Â鶹´«Ã½Ó³»­

Â鶹´«Ã½Ó³»­

Explore the latest content from across our publications
Join The Â鶹´«Ã½Ó³»­

Log In

Forgot Password?
Create New Account

Loading... please wait

2021 Annual Meeting | Headache Posters

This program spans the entire conference
This program will be presented both in-person and online
This program is not expected to be available in the meeting's On Demand product.
Scientific Poster Session
Headache
0.00 credit
COVID-19

Program Materials Program Evaluations

Event Timeline
07:00 AM - 05:00 PM EDT Abstract 001 - Consistent efficacy and safety of erenumab over time in patients with episodic migraine who completed a 5-year, open-label extension study
Messoud Ashina, MD, PhD
07:00 AM - 05:00 PM EDT Abstract 002 - Long-term Use of Rimegepant 75 mg for the Acute Treatment of Migraine Reduces Use of Analgesics and Antiemetics
David B. Kudrow, MD
07:00 AM - 05:00 PM EDT Abstract 003 - Randomized, Controlled Trial of Lasmiditan over Four Migraine Attacks: Consistency Findings
Judith Krikke
07:00 AM - 05:00 PM EDT Abstract 004 - Long-Term Safety of Rimegepant 75 mg for the Acute Treatment of Migraine in Adults With a History of Triptan Treatment Failure
Kathleen B. Mullin, MD
07:00 AM - 05:00 PM EDT Abstract 005 - Consistency of Effect with Galcanezumab Across Multiple Cluster Periods in Episodic Cluster Headache
Brian M. Plato, DO
07:00 AM - 05:00 PM EDT Abstract 006 - Acute Treatment with Rimegepant 75 mg Confers Long Term Improvements in Median Time to 30% and 50% Reductions in Monthly Migraine Days – Post Hoc Results from an Open Label Safety Study (BHVN-3000-201)
Gilbert J. L'Italien
07:00 AM - 05:00 PM EDT Abstract 007 - Efficacy in Patients Switching from Quarterly to Monthly Fremanezumab or Maintained on Monthly Fremanezumab Treatment Over 6 Months in the Phase 3b FOCUS Study
Jonathan P. Gladstone, MD
07:00 AM - 05:00 PM EDT Abstract 008 - Rimegepant is Safe and Tolerable for the Acute Treatment of Migraine in Patients Using Preventive Migraine Medications: Results from a Long-Term Open-Label Safety Study
Jack D. Schim, MD, FÂ鶹´«Ã½Ó³»­
07:00 AM - 05:00 PM EDT Abstract 009 - Randomized, Controlled Trial of Lasmiditan over Four Migraine Attacks: First Attack Findings
07:00 AM - 05:00 PM EDT Abstract 010 - Pharmacokinetics, Safety, and Tolerability of Ubrogepant for the Acute Treatment of Migraine Following Coadministration With Preventive Monoclonal Antibody Treatment
Janette Contreras-De Lama
07:00 AM - 05:00 PM EDT Abstract 011 - Real-World Evidence for Control of Patients With Chronic Migraine Who Received Calcitonin Gene?Related Peptide (CGRP) Monoclonal Antibody Therapy Added to OnabotulinumtoxinA Treatment
Andrew M. Blumenfeld, MD, FÂ鶹´«Ã½Ó³»­
07:00 AM - 05:00 PM EDT Abstract 012 - Real-World Evidence for Control of Chronic Migraine (CM) in Patients Meeting American Headache Society (AHS) Criteria Who Received Calcitonin Gene?Related Peptide Monoclonal Antibody (CGRPmAb) Therapy Added to OnabotulinumtoxinA Treatment
Andrew M. Blumenfeld, MD, FÂ鶹´«Ã½Ó³»­
07:00 AM - 05:00 PM EDT Abstract 013 - A long-term, open label Safety and Tolerability Study Of Precision Olfactory Delivery of DHE in Acute Migraine Treatment (STOP 301): Exploratory Efficacy Results
Sheena K. Aurora, MD
07:00 AM - 05:00 PM EDT Abstract 014 - Rimegepant 75 mg for the Acute Treatment of Migraine in Adults With Frequent Migraine: Long-Term Safety and Clinical Improvement Versus Baseline
Kathleen B. Mullin, MD
07:00 AM - 05:00 PM EDT Abstract 015 - Intranasal Ketamine as a Promising Acute Treatment for Refractory Headache
Jade S. Park, MD
07:00 AM - 05:00 PM EDT Abstract 016 - Rimegepant for the Acute Treatment of Migraine in Patients with a History of Triptan Treatment Failure: Pooled Results From 3 Phase 3 Clinical Trials
Christopher Jensen, PharmD
07:00 AM - 05:00 PM EDT Abstract 017 - Acute Treatment with Rimegepant 75 mg Confers Clinically Relevant Improvement in Lost Time (Days) Due to Migraine: Results From a 1-Year, Open-Label Safety Study (BHV3000-201)
Gilbert J. L'Italien
07:00 AM - 05:00 PM EDT Abstract 018 - A Phase 2/3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Rimegepant for the Preventive Treatment of Migraine
Robert Croop, MD
07:00 AM - 05:00 PM EDT Abstract 019 - Relation between intervals of the menstrual cycle and presentation to the Emergency Department for headache
Crystal Jicha, MD
07:00 AM - 05:00 PM EDT Abstract 020 - Does Wearing Off of Efficacy Occur in Galcanezumab-Treated Patients at the End of the Monthly Treatment Cycle: A Post Hoc Analysis of Four Phase 3 Randomized Trials
Jessica Ailani, MD, FÂ鶹´«Ã½Ó³»­
07:00 AM - 05:00 PM EDT Abstract 021 - Early Reductions in Headache Severity and Duration With Fremanezumab Treatment in the Randomized, Double-blind Phase 3b FOCUS study
Messoud Ashina, MD, PhD
07:00 AM - 05:00 PM EDT Abstract 022 - Eptinezumab Treatment Initiated During a Migraine Attack Prolonged the Time to Next Migraine and Improved HIT-6 Outcomes in the RELIEF Study
Peter J. McAllister, MD, FÂ鶹´«Ã½Ó³»­
07:00 AM - 05:00 PM EDT Abstract 023 - Long-term Efficacy of Fremanezumab in Patients With Chronic or Episodic Migraine Who Were Inadequate Responders to Initial Fremanezumab Treatment
Stephen D. Silberstein, MD, FÂ鶹´«Ã½Ó³»­
07:00 AM - 05:00 PM EDT Abstract 024 - Efficacy of Fremanezumab in Patients With Lower and Higher Frequency Chronic Migraine
Peter J. McAllister, MD, FÂ鶹´«Ã½Ó³»­
07:00 AM - 05:00 PM EDT Abstract 025 - Interictal Burden of Migraine: Correlations with Other Measures of Migraine Burden and Effects of Galcanezumab Migraine-Preventive Treatment
Claire H. Sandoe, MD
07:00 AM - 05:00 PM EDT Abstract 026 - Atogepant Improved Patient-Reported Outcome (PRO) Measures of Activity Impairment in Migraine-Diary and Headache Impact Test in a 12-Week, Double-blind, Randomized Phase 3 (ADVANCE) Trial for Preventive Treatment of Migraine
Richard B. Lipton, MD, FÂ鶹´«Ã½Ó³»­
07:00 AM - 05:00 PM EDT Abstract 027 - Impact of Fremanezumab on Disability Severity in Patients With Episodic and Chronic Migraine: Pooled Results of 3 Randomized, Double-blind, Placebo-controlled Phase 3 Studies
Abraham J. Nagy, MD
07:00 AM - 05:00 PM EDT Abstract 028 - Remote Electrical Neuromodulation for the Acute Treatment of Migraine in Adolescents
Andrew D. Hershey, MD, PhD, FAHS, FÂ鶹´«Ã½Ó³»­
07:00 AM - 05:00 PM EDT Abstract 029 - A Phase 2 Study of Fremanezumab as a Treatment for Posttraumatic Headache in Adult Patients
Egilius L. Spierings, MD, PhD
07:00 AM - 05:00 PM EDT Abstract 030 - Remote Electrical Neuromodulation for the Acute Treatment of Chronic Migraine
Brian Grosberg, MD
07:00 AM - 05:00 PM EDT Abstract 031 - US Real-world Effectiveness of Quarterly and Monthly Fremanezumab for Reducing Migraine Days and Headache Days in Adult Patients With Migraine
Joshua M. Cohen, MD
07:00 AM - 05:00 PM EDT Abstract 032 - Comparative Effectiveness of Erenumab versus Oral Preventive Medications among Migraine Patients: A US Claims Database Study
Stewart J. Tepper, MD
07:00 AM - 05:00 PM EDT Abstract 033 - Efficacy and Safety of Eptinezumab Initiated During a Migraine Attack: Results from the RELIEF Study
Paul Winner, DO, FÂ鶹´«Ã½Ó³»­
07:00 AM - 05:00 PM EDT Abstract 034 - Cardiovascular Safety of Fremanezumab in Patients With Migraine and Cardiovascular Medical History or Risk Factors: A Pooled Analysis of Phase 3 Studies
Stephanie J. Nahas, MD, FÂ鶹´«Ã½Ó³»­
07:00 AM - 05:00 PM EDT Abstract 035 - Healthcare utilization in patients with acute migraine: pre- and post-treatment with INP104 in a phase 3 study
Carrie Dougherty, MD, FÂ鶹´«Ã½Ó³»­
07:00 AM - 05:00 PM EDT Abstract 036 - Atogepant Improved Patient-Reported Migraine-Specific Quality of Life in a 12-Week Phase 3 (ADVANCE) Trial for Preventive Treatment of Migraine
David W. Dodick, MD, FÂ鶹´«Ã½Ó³»­
07:00 AM - 05:00 PM EDT Abstract 037 - Lasmiditan is Effective in the Acute Treatment of Migraine in Patients with Insufficient Response to Triptans: Findings from the CENTURION Study
Uwe Reuter
07:00 AM - 05:00 PM EDT Abstract 038 - Cardiovascular Safety Results of INP104 (POD-DHE) from the STOP 301 Phase 3 Study
Karen Craig
07:00 AM - 05:00 PM EDT Abstract 039 - Psychometric Evaluation of the Activity Impairment in Migraine-Diary (AIM-D) Using Data from a Phase 3 Clinical Trial (ADVANCE) in Patients with Episodic Migraine
Pranav Gandhi
07:00 AM - 05:00 PM EDT Abstract 040 - Safety and Tolerability of Ubrogepant Within Various Demographic and Clinical Characteristic Subgroups
Jessica Ailani, MD, FÂ鶹´«Ã½Ó³»­
07:00 AM - 05:00 PM EDT Abstract 041 - Real-World Safety and Efficacy of 155-195U OnabotulinumtoxinA in Participants With Chronic Migraine: Results From the REPOSE Study
Katherine Sommer
07:00 AM - 05:00 PM EDT Abstract 042 - A Phase 1, Open-Label, Single-Dose Pharmacokinetic Study of Lasmiditan in Paediatric Patients with Migraine
07:00 AM - 05:00 PM EDT Abstract 043 - Comparison of Efficacy Outcomes in Trials Using a M207 in the Acute Treatment of a Single Migraine or Multiple Migraines
Donald Kellerman
07:00 AM - 05:00 PM EDT Abstract 044 - Risk of Hypertension in Erenumab-treated Patients With Migraine in Clinical Trials and in the Postmarketing Setting
David W. Dodick, MD, FÂ鶹´«Ã½Ó³»­
07:00 AM - 05:00 PM EDT Abstract 045 - Tolerability of Lasmiditan in Elderly Patients with Migraine
Zubair Ahmed, MD
07:00 AM - 05:00 PM EDT Abstract 046 - Efficacy of Fremanezumab in Patients With Moderate and Higher Frequency Episodic Migraine
Stephanie J. Nahas, MD, FÂ鶹´«Ã½Ó³»­
07:00 AM - 05:00 PM EDT Abstract 047 - Design and Population characteristics of patients treated with monoclonal antibody erenumab for assessment of long-term safety and tolerability and frequency of drug holidays in Germany (APOLLON)
Sonja Ortler, MD
07:00 AM - 05:00 PM EDT Abstract 049 - Characterizing Preventive Treatment Gaps in Migraine: Results from the CaMEO Study
Stephanie J. Nahas, MD, FÂ鶹´«Ã½Ó³»­
07:00 AM - 05:00 PM EDT Abstract 050 - Optimized Acute Treatment Is Associated With Productivity Gains in People With Migraine: Results From the Chronic Migraine Epidemiology and Outcomes (CaMEO) Study
Dawn C. Buse, PhD
07:00 AM - 05:00 PM EDT Abstract 051 - US Real-world Migraine-related Health Care Resource Utilization and Costs for Patients Initiating Fremanezumab
Michael Seminerio
07:00 AM - 05:00 PM EDT Abstract 052 - Services for Headache Disorder(s) among Men and Women Veterans across the Veterans Health Administration – a 10-year Cohort Study
Elizabeth Seng, PhD
07:00 AM - 05:00 PM EDT Abstract 053 - Headache and Pain Multimorbidity in a National Cohort of U.S. Veterans with Cluster Headache
Jason J. Sico, MD, FÂ鶹´«Ã½Ó³»­
07:00 AM - 05:00 PM EDT Abstract 054 - Use of predictive modeling to determine treatment-response to OTC Medications in Acute Migraine: Results from the American Migraine Prevalence and Prevention Study (AMPP)
Ali Ezzati, MD
07:00 AM - 05:00 PM EDT Abstract 055 - Migraine Patients Exhibit Increased Risk Of Developing Chronic Migraine With Sustained Triptan Treatment - Results From A Large-Scale Real-World Claims Analysis
Ali Mohajer, PhD
07:00 AM - 05:00 PM EDT Abstract 056 - Seeking Care, Diagnosis, and Acute Prescription for Migraine Among Those with Headache-Related Disability: Results of the OVERCOME Study
Susan Hutchinson
07:00 AM - 05:00 PM EDT Abstract 057 - Static and Dynamic Functional Connectivity Differences in Migraine compared to Healthy Controls
Catherine D. Chong, PhD, FÂ鶹´«Ã½Ó³»­
07:00 AM - 05:00 PM EDT Abstract 058 - DAGLa Inhibition as a Non-invasive and Translational Model of Episodic Headache
Aidan Levine
07:00 AM - 05:00 PM EDT Abstract 059 - Eptinezumab:CGRP Complex Structure and Characterization of the Ligand Binding Interface
07:00 AM - 05:00 PM EDT Abstract 060 - Disease-Specific Validation of the revised Utah Photophobia Symptom Impact Scale in Migraine Subjects
07:00 AM - 05:00 PM EDT Abstract 061 - Resting State Functional Connectivity Changes of the Pons in Migraine Patients: A Cross-Sectional and Longitudinal Study
Roberta Messina, MD, PhD
07:00 AM - 05:00 PM EDT Abstract 062 - Altered Functional Network Connectivity in Chronic Migraine: a Replication-Extension Study
Danielle D. DeSouza, PhD
07:00 AM - 05:00 PM EDT Abstract 063 - Novel Receptor Activity Mapping of Methysergide and its Metabolite, Methylergometrine, Provides a Mechanistic Rationale for both the Clinically Observed Efficacy and Risk of Fibrosis in Patients with Migraine
07:00 AM - 05:00 PM EDT Abstract 064 - Mass Balance and Metabolism of Carbon-14 Atogepant in Healthy Male Participants
Josh Rowe
07:00 AM - 05:00 PM EDT Abstract 065 - DHE Pharmacology Revisited: Does a broad receptor profile molecule treat the whole migraine?
Sheena K. Aurora, MD
07:00 AM - 05:00 PM EDT Abstract 066 - Exercised Brain in Pain: Quantification of Exercise in Migraine Patients Seen at a Large Tertiary Headache Center
Mason D. Dyess, DO
07:00 AM - 05:00 PM EDT Abstract 067 - Medication Overuse Headache in Chronic Migraine Patients Using Cannabis: A Case-Referent Study
Niushen Zhang, MD
07:00 AM - 05:00 PM EDT Abstract 068 - Survivors of Military Sexual Trauma face increased risk of Migraine Headaches and Worse Headache Care
John Ney, MD, MPH, FÂ鶹´«Ã½Ó³»­
07:00 AM - 05:00 PM EDT Abstract 069 - Joint Hypermobility Syndrome in Children and Adolescents with Headache: a retrospective study
Ankita Ghosh, MD
07:00 AM - 05:00 PM EDT Abstract 070 - Migrainous Infarction: Case series in a neurological center of Buenos Aires
Florencia Wainberg, MD
07:00 AM - 05:00 PM EDT Abstract 071 - Tardive Dyskinesia in Migraine
Wojciech Gryc, MD
07:00 AM - 05:00 PM EDT Abstract 072 - Association of migraine with hospitalization for mental health disorders in US adults
Liqi Shu, MD
07:00 AM - 05:00 PM EDT Abstract 073 - Impact of Remote Learning in Children with Primary Headache Syndromes
Theodora Andriotis, DO
07:00 AM - 05:00 PM EDT Abstract 074 - Increased Prevalence of Headache in Patients with Sensory Neuropathic Symptoms
Hsinlin T. Cheng, MD
07:00 AM - 05:00 PM EDT Abstract 075 - Air pollution, methane super-emitters, and oil and gas wells in Northern California: the relationship with migraine headache prevalence and exacerbation
Holly Elser, MD, PhD
07:00 AM - 05:00 PM EDT Abstract 076 - Clinical Manifestations of Stroke in Migraineurs
Merrill M. Brady Moe, MD
07:00 AM - 05:00 PM EDT Abstract 077 - Headache during SARS-CoV-2 infection as an early symptom associated with mild inflammation and pulmonary disease: a retrospective cohort study
Alicia Gonzalez-Martinez, MD
07:00 AM - 05:00 PM EDT Abstract 078 - Headache associated with personal protective equipment in healthcare workers during COVID-19 outbreak in a referral centre in Mexico
Rogelio Dominguez-Moreno, MD
07:00 AM - 05:00 PM EDT Abstract 079 - MRI findings in Neurosarcoidosis Patients with Headache as a Primary Presenting Symptom
Yamin Sallowm, MD
07:00 AM - 05:00 PM EDT Abstract 080 - Cure for the Uncommon CSF Leak: Surgical Outcomes of CSF-Venous Fistula Repair
Monique M. Montenegro, MD
07:00 AM - 05:00 PM EDT Abstract 081 - Carotid Cavernous Fistula Mimicking Hemicrania Continua
Kendra K. Davis
07:00 AM - 05:00 PM EDT Abstract 082 - Thunderclap Headache as Presentation of Autonomic Dysreflexia in a Woman With Neuromyelitis Optica. Case Report and Literature Review.
Veronica A. Moreno Gomez, MD
07:00 AM - 05:00 PM EDT Abstract 083 - Stroke-like Migraine Attacks after Radiation Therapy (SMART) Syndrome: “Stroke-Like Migraine or Migrainous Stroke?”
Ahmed Abbas, MD
07:00 AM - 05:00 PM EDT Abstract 084 - Headache as the Presenting Symptom of COVID-19 in Two Patients with a History of Migraine
Jyotika Singh
07:00 AM - 05:00 PM EDT Abstract 085 - Spontaneous Intracranial Hypotension Presenting as Postural Headache and Cranial VI Palsy: A Case Report
Leonard Shou, DO
07:00 AM - 05:00 PM EDT Abstract 086 - Acute migraine anesthetic nasal spray treatment during the COVID-19 pandemic
Sarah M. Bobker, MD
07:00 AM - 05:00 PM EDT Abstract 087 - Decreasing Burden of Chronic Migraine in Pregnancy by Addressing Medication Overuse Headache
Ami Cuneo, MD
07:00 AM - 05:00 PM EDT Abstract 088 - US Real-world Patient Characteristics, Acute Medication Use, and Treatment Patterns for Patients Initiating Fremanezumab
Michael Seminerio
07:00 AM - 05:00 PM EDT Abstract 089 - Migraine Patients Exhibit Increased Risk Of Opioid Dependence With Sustained Triptan Treatment - Results From A Large-Scale Real-World Claims Analysis
07:00 AM - 05:00 PM EDT Abstract 090 - Acute Migraine Medication and Medication Overuse Headache: A Systematic Literature Review
Alison Deighton
07:00 AM - 05:00 PM EDT Abstract 091 - Migraine Patients Exhibit Risk Of Medication Overuse Headache With Sustained Triptan Treatment - Results From A Large-Scale Real-World Claims Analysis
Ali Mohajer, PhD
07:00 AM - 05:00 PM EDT Abstract 092 - Developing an Outpatient Infusion Center for Treatment of Pediatric Headache Disorders Redirects Point of Care and Decreases Heath Care Costs
Hannah Shapiro, MD
07:00 AM - 05:00 PM EDT Abstract 093 - Early Utilization of SPG Block for the Treatment of Acute Migraine Headache in the Pediatric Emergency Department
Mary Haywood
07:00 AM - 05:00 PM EDT Abstract 094 - Safety and Efficacy of Repetitive Dihydroergotamine Infusion for the Acute Treatment of Refractory Chronic Migraine in Hospitalized Patients with Vascular Risk Factors
Clinton G. Lauritsen, MD
07:00 AM - 05:00 PM EDT Abstract 095 - Consecutive Headache-Free Days With OnabotulinumtoxinA Treatment in Patients With Chronic Migraine: A Pooled PREEMPT Analysis
Katherine Sommer
07:00 AM - 05:00 PM EDT Abstract 096 - What Role do Urgent Care Centers Play in Headache Management? A Quality Improvement Study of Select Urgent Care Facilities
Annika Ehrlich, DNP, FNP-C, AQH, CNRN
07:00 AM - 05:00 PM EDT Abstract 097 - Clinical Immunogenicity Evaluation of Eptinezumab, a Therapeutic Humanized Monoclonal Antibody for the Preventive Treatment of Migraine
Susan M. Pederson
07:00 AM - 05:00 PM EDT Abstract 098 - Single Therapeutic Doses of Atogepant Are Not Associated With a Clinically Relevant Drug-Drug Interaction When Coadministered With Acetaminophen or Naproxen
07:00 AM - 05:00 PM EDT Abstract 099 - Development of a Novel, Clinical-stage Drug for the Prevention of Migraine Based on Receptor Activity Mapping and Achievement of a Target Receptor Profile
07:00 AM - 05:00 PM EDT Abstract 100 - An Open-Label Study Evaluating the Pharmacokinetics and Safety of Diclofenac Potassium for Oral Solution for the Acute Treatment of Migraine With or Without Aura in Pediatric Participants
Jennifer W. McVige, MD, FÂ鶹´«Ã½Ó³»­
07:00 AM - 05:00 PM EDT Abstract 101 - Coadministration of Single Therapeutic Oral Doses of Atogepant and Sumatriptan Produces No Clinically Relevant Drug-Drug Interactions
07:00 AM - 05:00 PM EDT Abstract 102 - Evaluation of Pharmacokinetic Interactions and Safety of Atogepant Coadministered With Quinidine Gluconate
07:00 AM - 05:00 PM EDT Abstract 103 - Role of Circadian Rhythm on the Effectiveness of Onabotulinum Toxin A (BTA) Injections as Preventive Therapy for Chronic Migraines (CM)
Andres A. Arciniegas, MD, MSHA, MSHI
07:00 AM - 05:00 PM EDT Abstract 104 - Changes in the Muscles of Mastication in patients with Trigeminal Neuralgia: Lessons from the radiosurgical cohort.
Nasser Mohammed, MBBS
07:00 AM - 05:00 PM EDT Abstract 105 - Case Of Percutaneous Trigeminal Ganglion Block With Intraoperative Monitoring Of Blink Reflex For Refractory Trigeminal Neuralgia.
Sachin M. Bhagavan, MD
07:00 AM - 05:00 PM EDT Abstract 106 - The Application of Ultrasound in Diagnosis and Surveillance of Chronic Occipital Neuralgia
Elham Azizi, MD
07:00 AM - 05:00 PM EDT Abstract 107 - Preference for Rimegepant and Improved Clinical Global Impression of Change Among Adults With a History of Triptan Treatment Failure: Results from a Long-Term Open-Label Safety Study
Ira M. Turner, MD
07:00 AM - 05:00 PM EDT Abstract 108 - Low Rates of Rescue Medication Usage in Subjects Treated with a Single Dose of Rimegepant 75 mg for the Acute Treatment of Migraine: Results from 3 Phase 3 Clinical Trials
07:00 AM - 05:00 PM EDT Abstract 109 - Acute Treatment of Migraine with Rimegepant Improves Health Related Quality of Life in Adults With a History of Triptan Treatment Failure: Results from a Long-Term, Open-Label Safety Study
Ira M. Turner, MD
07:00 AM - 05:00 PM EDT Abstract 110 - Improved Functionality, Satisfaction, and Global Impression of Change With Ubrogepant for the Acute Treatment of Migraine in Triptan Insufficient Responders
Jordan Lateiner, MS, MBA
07:00 AM - 05:00 PM EDT Abstract 111 - A Novel Approach to Defining Success in the Acute Treatment of Migraine: Pooled Results From the ACHIEVE I and ACHIEVE II Trials
Richard B. Lipton, MD, FÂ鶹´«Ã½Ó³»­
07:00 AM - 05:00 PM EDT Abstract 112 - Lasmiditan Efficacy in Mild Versus Moderate or Severe Migraine Headaches
Maurice Vincent, MD, PhD
07:00 AM - 05:00 PM EDT Abstract 113 - Onset of Action of a Zolmitriptan Microneedle System (M207, Qtrypta™) for Migraine: Comparison with Recent Early Time to Onset Recommendations, Pain Relief Results and Placebo Response
Deborah I. Friedman, MD, MPH, FÂ鶹´«Ã½Ó³»­
07:00 AM - 05:00 PM EDT Abstract 114 - MSQ Utility Mapping of Rimegepant by Change in Monthly Migraine Days
Karissa Johnston
07:00 AM - 05:00 PM EDT Abstract 115 - Patient acceptability of INP104 aligns with the unmet needs identified in I-BEAM survey.
Stephen B. Shrewsbury, MD
07:00 AM - 05:00 PM EDT Abstract 116 - Discrete Choice Experiment to Understand Patient Preferences for Self-Injectable Preventive Treatments for Migraine – A quantitative pilot
Jaein Seo
07:00 AM - 05:00 PM EDT Abstract 117 - Evaluation of Cardiovascular Risks in Patients Treated With Longer-term Exposure to Galcanezumab
Richard Kovacs
07:00 AM - 05:00 PM EDT Abstract 118 - Number Needed to Treat/Harm for Fremanezumab in Patients Who Had Inadequate Response to 2-4 Prior Migraine Preventive Medication Classes
Messoud Ashina, MD, PhD
07:00 AM - 05:00 PM EDT Abstract 119 - Real-world Adherence, Persistence, Switching, and Reinitiation in Patients Prescribed AJOVY in US Physician Practices
07:00 AM - 05:00 PM EDT Abstract 120 - Real-world Reductions in Migraine and Headache Days for Patients With Chronic and Episodic Migraine Initiating Fremanezumab in the US
Joshua M. Cohen, MD
07:00 AM - 05:00 PM EDT Abstract 121 - Improvements in Patient-reported Migraine Pain Intensity and Composite Migraine Symptoms With Fremanezumab in the Real World
Alexander A. Mauskop, MD, FÂ鶹´«Ã½Ó³»­
07:00 AM - 05:00 PM EDT Abstract 122 - Baseline Comorbidities and Changes in Acute Medication Use by Quarterly and Monthly Dosing Regimen in Patients Prescribed AJOVY in US Physician Practices
Lynda Krasenbaum
07:00 AM - 05:00 PM EDT Abstract 123 - Real-World Adherence, Persistence, Switching, and Reinitiation by Quarterly and Monthly Dosing Regimen in Patients Prescribed AJOVY in US Physician Practices
07:00 AM - 05:00 PM EDT Abstract 124 - Safety and Tolerability of Eptinezumab in Patients With Migraine: A Pooled Analysis of 5 Clinical Trials
07:00 AM - 05:00 PM EDT Abstract 125 - Effect of Fremanezumab on the Total Burden of Migraine in Patients with Episodic or Chronic Migraine: Findings from 3 Randomized, Double-blind, Placebo-controlled Phase 3 Studies
Christina Sun-Edelstein, MD
07:00 AM - 05:00 PM EDT Abstract 126 - Single Center Experience of mAbs-CGRP Use for Migraine Prevention
Christopher J. Bondoc, MD
07:00 AM - 05:00 PM EDT Abstract 127 - Patient Preference for Early Onset of Efficacy in Migraine Prevention
Paul Winner, DO, FÂ鶹´«Ã½Ó³»­
07:00 AM - 05:00 PM EDT Abstract 128 - Adherence to Guidelines and Outcomes Among People with Migraine Receiving Preventive Medication
Richard B. Lipton, MD, FÂ鶹´«Ã½Ó³»­
07:00 AM - 05:00 PM EDT Abstract 129 - Estimated migraine acute-therapy savings, from MMD reduction achieved with preventive treatment
07:00 AM - 05:00 PM EDT Abstract 130 - Headache diagnosis and treatment: A knowledge and needs assessment among pain medicine specialists
07:00 AM - 05:00 PM EDT Abstract 132 - Effectiveness Of Nonpharmacologic Therapy In Migraine Prophylaxis
Anusha Badveli, DM
07:00 AM - 05:00 PM EDT Abstract 133 - Safety efficacy and tolerability of the calcitonin gene-related peptide monoclonal antibodies for migraine prevention treatment of migraine, Kuwait experience.
07:00 AM - 05:00 PM EDT Abstract 134 - Anti-Calcitonin Gene-Related Peptide Monoclonal Antibodies in the Treatment of Patients with Concussion
07:00 AM - 05:00 PM EDT Abstract 135 - Acute Onset of Thrombotic Thrombocytopenic Purpura after Erenumab Treatment: A Case Report
Jaspreet Johal, MD
07:00 AM - 05:00 PM EDT Abstract 136 - Episodic and Chronic Cluster Headache: Evaluation of Health-Related Quality of Life Impact and Estimation of Health-state Utilities
Antje Tockhorn-Heidenreich
07:00 AM - 05:00 PM EDT Abstract 137 - MIDAS Disability Grades are Associated with Total Health Care and Pharmaceutical Costs – A US-Based Real World Longitudinal Analysis
07:00 AM - 05:00 PM EDT Abstract 138 - Use of Medical Â鶹´«Ã½Ó³»­ Program to Identify Practice Gaps Among Neurologists in the Use of Preventive Therapies for the Management of Migraine
John Maeglin
07:00 AM - 05:00 PM EDT Abstract 139 - Migraine Science Collaborative: A Novel Innovative Web-based Networking and Communication Platform To Enhance And Advance Migraine Research
Monica P. Mallampalli, PhD
07:00 AM - 05:00 PM EDT Abstract 140 - Tracking the Evolution of Non-Headache Symptoms Through the Migraine Attack
Roberta Messina, MD, PhD
07:00 AM - 05:00 PM EDT Abstract 141 - Acute Quadriplegic Migraine Presenting As Spinal Cord Infarction.
Hashaam Arshad, MD, MBBS
07:00 AM - 05:00 PM EDT Abstract 142 - Vegetables and Fruits Intake and Brain in Pain Quantification of Vegetables and Fruits Servings in Migraine Patients at Large Tertiary Headache Center
07:00 AM - 05:00 PM EDT Abstract 143 - Impact of the Vega Healthcare Provider Report on Provider Satisfaction and Decision-Making Confidence in Simulated Patient Portal Visits for Migraine
Paul B. Rizzoli, MD, FÂ鶹´«Ã½Ó³»­
07:00 AM - 05:00 PM EDT Abstract 144 - Cranial Autonomic Symptoms in Migraine
Nazia Karsan, MBBS, PhD
07:00 AM - 05:00 PM EDT Abstract 145 - Polysomnography and Neuroendocrine Hormones in Subjective Cognitive Impaired Patients with Transformed Migraine
Mohammed A. ElSherif, MD, PhD, FÂ鶹´«Ã½Ó³»­
07:00 AM - 05:00 PM EDT Abstract 146 - A New Vision in Headache Medicine: A Survey of Headache Specialists' Utilization of Telehealth in Their Practice
Mia T. Minen, MD, FÂ鶹´«Ã½Ó³»­
Faculty Disclosures
Timothy R. Smith, MD The institution of Dr. Smith has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Nocira. The institution of Dr. Smith has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Vorso/Nesos. The institution of Dr. Smith has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alder/Lundbeck. The institution of Dr. Smith has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Amgen. The institution of Dr. Smith has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Allergan/Abbvie. The institution of Dr. Smith has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biohaven. The institution of Dr. Smith has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Lilly. The institution of Dr. Smith has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Neurolief. The institution of Dr. Smith has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Nocira. The institution of Dr. Smith has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Teva. The institution of Dr. Smith has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Theranica. The institution of Dr. Smith has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Amgen. The institution of Dr. Smith has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Abbvie/Allergan. The institution of Dr. Smith has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Biohaven. The institution of Dr. Smith has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Lilly. Dr. Smith has stock in United Health Group. The institution of Dr. Smith has received research support from Aeon. The institution of Dr. Smith has received research support from Alder/Lundbeck. The institution of Dr. Smith has received research support from Alnylam. The institution of Dr. Smith has received research support from Amgen. The institution of Dr. Smith has received research support from Abbvie/Allergan. The institution of Dr. Smith has received research support from Biohaven. The institution of an immediate family member of Dr. Smith has received research support from Eliem Pharmaceuticals. The institution of Dr. Smith has received research support from Lilly. The institution of Dr. Smith has received research support from Pfizer. The institution of Dr. Smith has received research support from Nocira. The institution of Dr. Smith has received research support from Novo Nordisk. The institution of Dr. Smith has received research support from Teva. The institution of Dr. Smith has received research support from Theranica. The institution of Dr. Smith has received research support from Vorso/Nesos. Dr. Smith has a non-compensated relationship as a Board Member with National Headache Foundation that is relevant to Â鶹´«Ã½Ó³»­ interests or activities.
David B. Kudrow, MD Dr. Kudrow has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for AbbVie. Dr. Kudrow has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for AbbVie.
No disclosure on file
Maria Goicochea No disclosure on file
Lakshminarasimhaiah Krishnamurthy, MD Dr. Krishnamurthy has nothing to disclose.
Janette Contreras-De Lama Janette Contreras-De Lama has received personal compensation for serving as an employee of AbbVie. Janette Contreras-De Lama has stock in AbbVie.
Stephen D. Silberstein, MD, FÂ鶹´«Ã½Ó³»­ Dr. Silberstein has received publishing royalties from a publication relating to health care.
Marianthi-Anna Kioumourtzoglou Marianthi-Anna Kioumourtzoglou, 7882 has nothing to disclose.
Jaspreet Johal, MD Dr. Johal has nothing to disclose.
Brent Allan No disclosure on file
Barbara Schaeffler No disclosure on file
Jasem Y. Al-Hashel, MD Dr. Al-Hashel has nothing to disclose.
Henna Sawhney, MBBS Dr. Sawhney has nothing to disclose.
David M. Biondi, DO, FÂ鶹´«Ã½Ó³»­ Dr. Biondi has received personal compensation for serving as an employee of Cohen Veterans Bioscience, Inc. Dr. Biondi has received personal compensation for serving as an employee of Alder Biopharmaceuticals, Inc. Dr. Biondi has received stock or an ownership interest from Johnson & Johnson . The institution of Dr. Biondi has received research support from US Department of Defense .
Juline Bryson, MD Dr. Bryson has received personal compensation for serving as an employee of Teva Pharmaceuticals. Dr. Bryson has or had stock in Teva .
Jaein Seo Jaein Seo has received personal compensation for serving as an employee of Evidera.
Brian M. Plato, DO Dr. Plato has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Amgen. Dr. Plato has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Allergan. Dr. Plato has received personal compensation in the range of $50,000-$99,999 for serving on a Speakers Bureau for Amgen. Dr. Plato has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Allergan. Dr. Plato has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Eli Lilly. Dr. Plato has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Biohaven.
Jakub Jedynak Jakub Jedynak has received personal compensation for serving as an employee of Lilly. Jakub Jedynak has received stock or an ownership interest from Lilly.
Alicia Gonzalez-Martinez, MD Dr. Gonzalez-Martinez has nothing to disclose.
Theodora Andriotis, DO Dr. Andriotis has nothing to disclose.
Nathan L. Bennett, MD Dr. Bennett has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Allergan / AbbVie. Dr. Bennett has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Amgen. Dr. Bennett has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Teva. Dr. Bennett has received personal compensation in the range of $50,000-$99,999 for serving on a Speakers Bureau for Allergan / Abbvie. Dr. Bennett has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Amgen. Dr. Bennett has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Teva. Dr. Bennett has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Biohaven.
Muhammad F. Ishfaq, MD Dr. Ishfaq has nothing to disclose.
Massimo Filippi, MD, FÂ鶹´«Ã½Ó³»­ Dr. Filippi has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Alexion, Almirall, Biogen, Merck, Novartis, Roche, Sanofi. Dr. Filippi has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion, Biogen, Bristol-Myers Squibb, Merck, Novartis, Roche, Sanofi, Sanofi-Aventis, Sanofi-Genzyme, Takeda. Dr. Filippi has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Bayer, Biogen, Celgene, Chiesi Italia SpA, Eli Lilly, Genzyme, Janssen, Merck-Serono, Neopharmed Gentili, Novartis, Novo Nordisk, Roche, Sanofi, Takeda, and TEVA. Dr. Filippi has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Springer Nature. The institution of Dr. Filippi has received research support from Biogen Idec, Merck-Serono, Novartis, Roche, the Italian Ministry of Health, the Italian Ministry of University and Research, and Fondazione Italiana Sclerosi Multipla.
Daniel Mandel, MD Dr. Mandel has nothing to disclose.
Addie Peretz, MD Dr. Peretz has nothing to disclose.
Angela J. Argyropoulos, MD Dr. Argyropoulos has nothing to disclose.
Corey Goldsmith, MD, FÂ鶹´«Ã½Ó³»­ Dr. Goldsmith has received publishing royalties from a publication relating to health care.
Jonathan P. Gladstone, MD Dr. Gladstone has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Lily. Dr. Gladstone has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novartis. Dr. Gladstone has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Allergan. Dr. Gladstone has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Lily. Dr. Gladstone has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. Dr. Gladstone has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Teva. Dr. Gladstone has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Allergan. Dr. Gladstone has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Aralez. Dr. Gladstone has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Lundbeck. Dr. Gladstone has received publishing royalties from a publication relating to health care.
Ellen Dennehy Ellen Dennehy has received personal compensation for serving as an employee of Eli Lilly. Ellen Dennehy has stock in Eli Lilly.
Anand R. Shewale Anand R. Shewale has received personal compensation for serving as an employee of AbbVie. Anand R. Shewale has stock in AbbVie.
George Chakhava, MD, PhD Prof. Chakhava has nothing to disclose.
Sonja Ortler, MD Dr. Ortler has received personal compensation for serving as an employee of Novartis Pharma GmbH.
Holland Detke Holland Detke has received personal compensation for serving as an employee of Eli Lilly and Company. Holland Detke has received stock or an ownership interest from Eli Lilly and Company.
Dylan Lis Mr. Lis has nothing to disclose.
Stephanie J. Nahas, MD, FÂ鶹´«Ã½Ó³»­ Dr. Nahas has received personal compensation in the range of $50,000-$99,999 for serving as a Consultant for AbbVie. Dr. Nahas has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Eli Lilly. Dr. Nahas has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Pfizer. Dr. Nahas has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Axsome. Dr. Nahas has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Amneal. Dr. Nahas has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Bausch Health. Dr. Nahas has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Ipsen. Dr. Nahas has received publishing royalties from a publication relating to health care. Dr. Nahas has received publishing royalties from a publication relating to health care. Dr. Nahas has received personal compensation in the range of $500-$4,999 for serving as a expert for CME activities with Medscape/WebMD. Dr. Nahas has a non-compensated relationship as a Board Member-at-Large with American Headache Society that is relevant to Â鶹´«Ã½Ó³»­ interests or activities. Dr. Nahas has a non-compensated relationship as a Executive Board Member with The Headache Alliance that is relevant to Â鶹´«Ã½Ó³»­ interests or activities.
Alexander A. Mauskop, MD, FÂ鶹´«Ã½Ó³»­ Dr. Mauskop has received personal compensation in the range of $100,000-$499,999 for serving as a Consultant for Allergan. Dr. Mauskop has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Eli Lily. Dr. Mauskop has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Lundbeck. Dr. Mauskop has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Biohaven. Dr. Mauskop has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Amgen. Dr. Mauskop has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Teva. Dr. Mauskop has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Allergan.
Claire H. Sandoe, MD Dr. Sandoe has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Lundbeck. Dr. Sandoe has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Abbvie. The institution of Dr. Sandoe has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Abbvie. Dr. Sandoe has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Pfizer. Dr. Sandoe has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Teva. Dr. Sandoe has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Searchlight Pharma. Dr. Sandoe has a non-compensated relationship as a Board Member with Canadian Headache Society that is relevant to Â鶹´«Ã½Ó³»­ interests or activities. Dr. Sandoe has a non-compensated relationship as a Board Member with American Migraine Foundation that is relevant to Â鶹´«Ã½Ó³»­ interests or activities.
Sihui Zhao No disclosure on file
Richard B. Lipton, MD, FÂ鶹´«Ã½Ó³»­ Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Allergan/Abbvie. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Amgen. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Biohaven. Dr. Lipton has received personal compensation in the range of $50,000-$99,999 for serving as a Consultant for Eli Lilly. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Lundbeck. Dr. Lipton has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for GlaxoSmithKline. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Teva. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Vedanta. Dr. Lipton has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Merck. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Grifols. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Pfizer. Dr. Lipton has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Axon. Dr. Lipton has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Satsuma. Dr. Lipton has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Genentech. Dr. Lipton has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Cool Tech. Dr. Lipton has received personal compensation in the range of $500-$4,999 for serving as a Consultant for BDSI. Dr. Lipton has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Linpharma. Dr. Lipton has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Axsome. Dr. Lipton has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Clexio. Dr. Lipton has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Shiratronics. Dr. Lipton has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Allergan/Abbvie. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biohaven. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Eli Lilly. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Lundbeck. Dr. Lipton has or had stock in Biohaven.Dr. Lipton has or had stock in Manistee.Dr. Lipton has or had stock in Axon.Dr. Lipton has or had stock in CoolTech. The institution of Dr. Lipton has received research support from Teva. The institution of Dr. Lipton has received research support from Amgen. The institution of Dr. Lipton has received research support from Allergan/Abbvie. The institution of Dr. Lipton has received research support from Gammacore. The institution of Dr. Lipton has received research support from Axsome. The institution of Dr. Lipton has received research support from Charleston Labs. The institution of Dr. Lipton has received research support from Eli Lilly. The institution of Dr. Lipton has received research support from Satsuma. The institution of Dr. Lipton has received research support from NIH . The institution of Dr. Lipton has received research support from Veterans Administration. Dr. Lipton has received publishing royalties from a publication relating to health care.
Susan M. Pederson Susan M. Pederson has nothing to disclose.
Aniket Natekar Mr. Natekar has nothing to disclose.
Clinton G. Lauritsen, MD Dr. Lauritsen has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Allergan. Dr. Lauritsen has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Amgen. Dr. Lauritsen has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Allergan.
Sung Y. Yu Sung Y. Yu has received personal compensation for serving as an employee of Abbvie. Sung Y. Yu has received stock or an ownership interest from Abbvie.
Abhijeet Jakate, PhD No disclosure on file
Phebe Kemmer, PhD Dr. Kemmer has received personal compensation for serving as an employee of Eli Lilly and Company. Dr. Kemmer has received stock or an ownership interest from Eli Lilly and Company.
Elizabeth Brunner Elizabeth Brunner has received personal compensation for serving as an employee of Lundbeck. Elizabeth Brunner has received stock or an ownership interest from Lundbeck.
Jin Li, MD, PhD, FÂ鶹´«Ã½Ó³»­ Dr. Li has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Abbvie. Dr. Li has a non-compensated relationship as a member, woman leadership committee with Â鶹´«Ã½Ó³»­ that is relevant to Â鶹´«Ã½Ó³»­ interests or activities.
Elham Azizi, MD Dr. Azizi has nothing to disclose.
John Latham No disclosure on file
Natalia Murinova, MD, FÂ鶹´«Ã½Ó³»­ Dr. Murinova has nothing to disclose.
Robert E. Shapiro, MD, PhD, FÂ鶹´«Ã½Ó³»­ Dr. Shapiro has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Lilly. Dr. Shapiro has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Lilly. Dr. Shapiro has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Theranica. Dr. Shapiro has received personal compensation in the range of $10,000-$49,999 for serving as an officer or member of the Board of Directors for Headache Cooperative of New England. Dr. Shapiro has received personal compensation in the range of $5,000-$9,999 for serving as an Expert Witness for EEOC.
J S. Andrews J Scott Andrews has received personal compensation for serving as an employee of Eli Lilly & Company. J Scott Andrews has received stock or an ownership interest from Eli Lilly & Company.
Larry "LC" Charleston IV, MD, MSc, FAHS, FANA, FÂ鶹´«Ã½Ó³»­ Dr. Charleston has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for AbbVie. Dr. Charleston has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Amneal Pharmaceuticals. Dr. Charleston has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Satsuma Pharmaceuticals. Dr. Charleston has received personal compensation in the range of $500-$4,999 for serving as a Consultant for LinPharma. Dr. Charleston has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Haleon. Dr. Charleston has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Pfizer. The institution of Dr. Charleston has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Axsome. Dr. Charleston has or had stock in Mi-Helper Inc..Dr. Charleston has a non-compensated relationship as a Associate Editor with Headache Journal: The Journal of Head and Face Pain that is relevant to Â鶹´«Ã½Ó³»­ interests or activities. Dr. Charleston has a non-compensated relationship as a Board Member with Clinical Neurological Society of America that is relevant to Â鶹´«Ã½Ó³»­ interests or activities. Dr. Charleston has a non-compensated relationship as a Chair, EDI Advisory Committee (Non-voting Board Member) with American Headache Society that is relevant to Â鶹´«Ã½Ó³»­ interests or activities.
Maurice Vincent, MD, PhD Prof. Vincent has received personal compensation for serving as an employee of Eli Lilly and Company. Prof. Vincent has stock in Eli Lilly and Company.
Matias Ferraris Matias Ferraris has received personal compensation for serving as an employee of Novartis Pharma AG. An immediate family member of Matias Ferraris has received stock or an ownership interest from Novartis Pharma AG.
Ali Mohajer, PhD Dr. Mohajer has received personal compensation for serving as an employee of Qral Group, LLC.
Hashaam Arshad, MD, MBBS No disclosure on file
Mohammed A. ElSherif, MD, PhD, FÂ鶹´«Ã½Ó³»­ Dr. ElSherif has nothing to disclose.
William B. Young, MD, FÂ鶹´«Ã½Ó³»­ Dr. Young has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Theranica. Dr. Young has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Allergan. Dr. Young has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biohaven Pharmaceuticals. Dr. Young has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Eli Lilly and Company. Dr. Young has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Teva. Dr. Young has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Biohaven Pharmaceuticals Inc. Dr. Young has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Eli Lilly and Company. Dr. Young has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Teva. Dr. Young has received personal compensation in the range of $0-$499 for serving as an officer or member of the Board of Directors for Coalition for Headache and Migraine Patients. Dr. Young has received personal compensation in the range of $0-$499 for serving as an officer or member of the Board of Directors for Miles for Migraine. The institution of Dr. Young has received research support from Amgen. The institution of Dr. Young has received research support from Cumberland. The institution of Dr. Young has received research support from Eli Lilly. The institution of Dr. Young has received research support from Novartis. The institution of Dr. Young has received research support from PCORI. The institution of Dr. Young has received research support from Satsuma. The institution of Dr. Young has received research support from Scion. The institution of Dr. Young has received research support from Teva. The institution of Dr. Young has received research support from Zosano.
Zubair Ahmed, MD Dr. Ahmed has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Eli Lilly. Dr. Ahmed has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Abbvie. Dr. Ahmed has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Biohaven.
Jyotika Singh Ms. Singh has nothing to disclose.
Ilaria Cetta, MD Dr. Cetta has nothing to disclose.
Andrew M. Blumenfeld, MD, FÂ鶹´«Ã½Ó³»­ Dr. Blumenfeld has received personal compensation for serving as an employee of The Los Angeles Headache Center. Dr. Blumenfeld has received personal compensation in the range of $100,000-$499,999 for serving as a Consultant for Allergan/Abbvie. Dr. Blumenfeld has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Best Doctors. Dr. Blumenfeld has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Guidepoint. Dr. Blumenfeld has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for GLG. Dr. Blumenfeld has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Theranica. Dr. Blumenfeld has received personal compensation in the range of $100,000-$499,999 for serving as a Consultant for Aeon. Dr. Blumenfeld has received personal compensation in the range of $100,000-$499,999 for serving as a Consultant for Revance. Dr. Blumenfeld has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Lilly. Dr. Blumenfeld has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Pfizer. Dr. Blumenfeld has received personal compensation in the range of $50,000-$99,999 for serving as a Consultant for Lundbeck. Dr. Blumenfeld has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Teva. Dr. Blumenfeld has received personal compensation in the range of $50,000-$99,999 for serving as a Consultant for Axsome. Dr. Blumenfeld has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Axon. Dr. Blumenfeld has received personal compensation in the range of $100,000-$499,999 for serving as a Consultant for Cedar Sinai. Dr. Blumenfeld has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Allergan/Abbvie. Dr. Blumenfeld has received personal compensation in the range of $100,000-$499,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Aeon. Dr. Blumenfeld has received personal compensation in the range of $100,000-$499,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Revance. Dr. Blumenfeld has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Theranica. Dr. Blumenfeld has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Axsome. Dr. Blumenfeld has received personal compensation in the range of $100,000-$499,999 for serving on a Speakers Bureau for Allergan/Abbvie. Dr. Blumenfeld has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Amgen. Dr. Blumenfeld has received personal compensation in the range of $50,000-$99,999 for serving on a Speakers Bureau for Teva. Dr. Blumenfeld has received personal compensation in the range of $50,000-$99,999 for serving on a Speakers Bureau for Lilly. Dr. Blumenfeld has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Biohaven. Dr. Blumenfeld has received personal compensation in the range of $50,000-$99,999 for serving on a Speakers Bureau for Lundbeck. Dr. Blumenfeld has received personal compensation in the range of $50,000-$99,999 for serving on a Speakers Bureau for AXSOME.
Ira M. Turner, MD Dr. Turner has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Allergan, Amgen, Novartis, Teva, Lilly, Lundbeck, Biohaven,Impel. Dr. Turner has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Amgen, Teva, Allergan, Biohaven, Lilly, Lundbeck, Theranica, Revance. Dr. Turner has received personal compensation in the range of $100,000-$499,999 for serving on a Speakers Bureau for Allergan, Amgen, Biohaven, Teva, Novartis, Lundbeck, Lilly. The institution of Dr. Turner has received research support from Allergan, Amgen, Biohaven, Lilly, Lundbeck, Theranica.
Messoud Ashina, MD, PhD Dr. Ashina has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for AbbVie. Dr. Ashina has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Eli Lilly. Dr. Ashina has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Lundbeck. Dr. Ashina has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novartis. Dr. Ashina has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Teva. Dr. Ashina has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Pfizer. Dr. Ashina has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Astra Zeneca. Dr. Ashina has received personal compensation in the range of $500-$4,999 for serving as a Consultant for GlaxoSmithKline. Dr. Ashina has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Incyte. The institution of Dr. Ashina has received research support from The Lundbeck Foundation. The institution of Dr. Ashina has received research support from Novo Nordisk Foundation . The institution of Dr. Ashina has received research support from Danish National Research Foundation . Dr. Ashina has received publishing royalties from a publication relating to health care.
Benjamin W. Friedman, MD, MS Benjamin W. Friedman, MD, MS has nothing to disclose.
Krista Schroeder Krista Schroeder has received personal compensation for serving as an employee of Eli Lilly and Company.
John Ney, MD, MPH, FÂ鶹´«Ã½Ó³»­ Dr. Ney has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Ceribell. Dr. Ney has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Neurology Clinical Practice.
Mario Ortega No disclosure on file
Christopher Jensen, PharmD Dr. Jensen has received personal compensation for serving as an employee of Biohaven Pharmaceuticals. Dr. Jensen has stock in Biohaven Pharmaceuticals.
Antje Tockhorn-Heidenreich Antje Tockhorn-Heidenreich has received personal compensation for serving as an employee of Eli Lilly and Company. An immediate family member of Antje Tockhorn-Heidenreich has received personal compensation for serving as an employee of Evidera. Antje Tockhorn-Heidenreich has received stock or an ownership interest from Eli Lilly and Company . An immediate family member of Antje Tockhorn-Heidenreich has received stock or an ownership interest from PPD.
Helen C. Haley Miss Haley has nothing to disclose.
Vi Le Vi Le has nothing to disclose.
John Maeglin Mr. Maeglin has nothing to disclose.
Sarah A. Mangold, DO Ms. Mangold has nothing to disclose.
Brett Dabruzzo, PharmD Dr. Dabruzzo has received personal compensation for serving as an employee of AbbVie. Dr. Dabruzzo has stock in AbbVie.
Clayton Shanahan Mr. Shanahan has nothing to disclose.
Alison Deighton Alison Deighton has nothing to disclose.
Laszlo Mechtler, MD, FEAN, FASN, FAHS, FÂ鶹´«Ã½Ó³»­ Dr. Mechtler has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Impel Pharma. Dr. Mechtler has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Abbvie. Dr. Mechtler has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Hyperfine. Dr. Mechtler has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Abbvie. Dr. Mechtler has received personal compensation in the range of $10,000-$49,999 for serving as an officer or member of the Board of Directors for Genomate Health. The institution of Dr. Mechtler has received research support from The Harry Dent Family Foundation, Inc. The institution of Dr. Mechtler has received research support from Alpheus medical. The institution of Dr. Mechtler has received research support from Shiratronics. The institution of Dr. Mechtler has received research support from Abbvie Inc. The institution of Dr. Mechtler has received research support from Amgen. The institution of Dr. Mechtler has received research support from Eli Lilly Company. The institution of Dr. Mechtler has received research support from H. Lundbeck HS. The institution of Dr. Mechtler has received research support from Pfizer. The institution of Dr. Mechtler has received research support from Hyperfine. Dr. Mechtler has received personal compensation in the range of $100,000-$499,999 for serving as a Ownership interest with Neurology Practce Consortium GPO. Dr. Mechtler has a non-compensated relationship as a Board member with International Headache Society that is relevant to Â鶹´«Ã½Ó³»­ interests or activities.
Joshua M. Cohen, MD No disclosure on file
Jason Hinzman Jason Hinzman has received personal compensation for serving as an employee of Eli Lilly. Jason Hinzman has received stock or an ownership interest from Eli Lilly.
Raghav Govindarajan, MD, FÂ鶹´«Ã½Ó³»­ Dr. Govindarajan has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for MT pharma. Dr. Govindarajan has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion. Dr. Govindarajan has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Argenx. Dr. Govindarajan has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Catalyst. Dr. Govindarajan has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche . Dr. Govindarajan has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sarepta. Dr. Govindarajan has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Amicus. Dr. Govindarajan has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for UCB. Dr. Govindarajan has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Alexion. Dr. Govindarajan has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for MT pharma . Dr. Govindarajan has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Catalyst. Dr. Govindarajan has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Argenx. Dr. Govindarajan has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Biohaven. Dr. Govindarajan has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for UCB. Dr. Govindarajan has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Takeda. Dr. Govindarajan has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Abbvie. The institution of Dr. Govindarajan has received research support from Band of Hope . The institution of Dr. Govindarajan has received research support from Alexion. Dr. Govindarajan has received publishing royalties from a publication relating to health care.
Kristina M. Fanning, PhD The institution of Dr. Fanning has received research support from Abbvie. The institution of Dr. Fanning has received research support from NYC Langone Health . The institution of Dr. Fanning has received research support from Uiversity of SC - Irvine. The institution of Dr. Fanning has received research support from AESARA.
Nina Y. Riggins, MD, FÂ鶹´«Ã½Ó³»­ Dr. Riggins has received personal compensation in the range of $500-$4,999 for serving as a Consultant for GLG Gerson Lehrman Group . Dr. Riggins has received personal compensation in the range of $500-$4,999 for serving as a Consultant for KLJ. Dr. Riggins has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Theranica. Dr. Riggins has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Teva. The institution of Dr. Riggins has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Lundbeck. The institution of Dr. Riggins has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Amneal Pharmaceuticals. Dr. Riggins has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for NeurologyLive, MJH Life Sciences. Dr. Riggins has received personal compensation in the range of $0-$499 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for SpringerNature. The institution of Dr. Riggins has received research support from ElectroCore (GammaCore). The institution of Dr. Riggins has received research support from Miles for Migraine. The institution of Dr. Riggins has received research support from Eli Lilly. Dr. Riggins has received publishing royalties from a publication relating to health care. Dr. Riggins has received publishing royalties from a publication relating to health care. Dr. Riggins has received publishing royalties from a publication relating to health care. Dr. Riggins has a non-compensated relationship as a PI on research study with TheraSpecs that is relevant to Â鶹´«Ã½Ó³»­ interests or activities. Dr. Riggins has a non-compensated relationship as a Advisory Board with NeurologyLive that is relevant to Â鶹´«Ã½Ó³»­ interests or activities. Dr. Riggins has a non-compensated relationship as a Member of the Board with Miles for Migraine that is relevant to Â鶹´«Ã½Ó³»­ interests or activities. Dr. Riggins has a non-compensated relationship as a PI in the study which used sphenocath device with Dolor Technologies that is relevant to Â鶹´«Ã½Ó³»­ interests or activities. Dr. Riggins has a non-compensated relationship as a PI with Theranica that is relevant to Â鶹´«Ã½Ó³»­ interests or activities.
Lynda Krasenbaum Lynda Krasenbaum has received personal compensation for serving as an employee of Teva Pharmaceuticals.
Melissa M. Cortez, DO The institution of Dr. Cortez has received research support from NIH NINDS. The institution of Dr. Cortez has received research support from Dysautonomia International. Dr. Cortez has received personal compensation in the range of $500-$4,999 for serving as a Content Expert, Reviewer, DSMB with NIH RECOVER project.
Jade S. Park, MD Dr. Park has nothing to disclose.
Yamin Sallowm, MD Dr. Sallowm has nothing to disclose.
Kayla Kaplan Kayla Kaplan has nothing to disclose.
Eric Pearlman, MD Dr. Pearlman has received personal compensation for serving as an employee of Eli Lilly and Co. Dr. Pearlman has received stock or an ownership interest from Eli Lilly and Co.
Umer Najib, MD, FÂ鶹´«Ã½Ó³»­ Dr. Najib has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Pfizer. Dr. Najib has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Lundbeck . Dr. Najib has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Abbvie . The institution of Dr. Najib has received research support from Eli Lilly. The institution of Dr. Najib has received research support from Abbvie.
Hamza I. Maqsood, MD Dr. Qureshi has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for AstraZeneca.
Abhishek Kengen, MD Dr. Kengen has nothing to disclose.
Jessica Ailani, MD, FÂ鶹´«Ã½Ó³»­ Dr. Ailani has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Abbvie. Dr. Ailani has received personal compensation in the range of $0-$499 for serving as a Consultant for Eli Lilly. Dr. Ailani has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Lundbeck. Dr. Ailani has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Pfizer. Dr. Ailani has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Ipsen. Dr. Ailani has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Merz. Dr. Ailani has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Aspya. Dr. Ailani has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Axsome. Dr. Ailani has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Bausch. Dr. Ailani has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Amneal. Dr. Ailani has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Satsuma. Dr. Ailani has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Kallyope. Dr. Ailani has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Self Magazine. The institution of Dr. Ailani has received research support from Ipsen. The institution of Dr. Ailani has received research support from Parema. The institution of Dr. Ailani has received research support from Lundbeck. The institution of Dr. Ailani has received research support from Merz. The institution of Dr. Ailani has received research support from Pfizer. Dr. Ailani has received research support from Mi-Helper. The institution of Dr. Ailani has received research support from ShiraTronic. Dr. Ailani has a non-compensated relationship as a Executive Board Member with American Headache Society that is relevant to Â鶹´«Ã½Ó³»­ interests or activities.
Elyse Stock Elyse Stock has received personal compensation for serving as an employee of Biohaven Pharmaceuticals. An immediate family member of Elyse Stock has received personal compensation in the range of $100,000-$499,999 for serving as a Consultant for Biohaven Pharmaceuticals. An immediate family member of Elyse Stock has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Flagship Pioneering Management. An immediate family member of Elyse Stock has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Bristol-Myers Squibb. An immediate family member of Elyse Stock has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Optinose. An immediate family member of Elyse Stock has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Abpro. An immediate family member of Elyse Stock has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Adagio. Elyse Stock has received personal compensation in the range of $1,000,000+ for serving as an officer or member of the Board of Directors for Biohaven Pharmaceuticals. Elyse Stock has received stock or an ownership interest from Biohaven Pharmaceuticals. An immediate family member of Elyse Stock has received stock or an ownership interest from BIohaven Pharmaceuticals.
Kathleen B. Mullin, MD Dr. Mullin has received personal compensation in the range of $0-$499 for serving as a Consultant for Vorso. Dr. Mullin has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Impel. Dr. Mullin has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biohaven. Dr. Mullin has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Eli Lilly. Dr. Mullin has received personal compensation in the range of $0-$499 for serving as a Consultant for Theranica. Dr. Mullin has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Eli Lilly. Dr. Mullin has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Teva. Dr. Mullin has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Biohaven. Dr. Mullin has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Amgen. Dr. Mullin has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Pfizer. Dr. Mullin has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for AbbVie.
Sait Ashina, MD Dr. Ashina has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Eli Lilly. Dr. Ashina has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Allergan/Abbvie. Dr. Ashina has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Theranica. Dr. Ashina has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Linpharma. Dr. Ashina has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Teva. Dr. Ashina has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Lundbeck. Dr. Ashina has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Pfizer.
Jenny Guiracocha Jenny Guiracocha has nothing to disclose.
Bjoern Sperling Bjoern Sperling has received personal compensation for serving as an employee of Lundbeck . Bjoern Sperling has received personal compensation in the range of $10,000-$49,999 for serving as an officer or member of the Board of Directors for Rehaler . Bjoern Sperling has or had stock in Lundbeck .
Mat D. Davis Mat D. Davis has received personal compensation for serving as an employee of Teva pharmaceuticals. Mat D. Davis has received stock or an ownership interest from Teva Pharmaceuticals.
Hend Abulsayen, MD Dr. Abulsayen has nothing to disclose.
Joel M. Trugman, MD, FÂ鶹´«Ã½Ó³»­ Dr. Trugman has received personal compensation for serving as an employee of AbbVie. Dr. Trugman has stock in AbbVie.
Hsinlin T. Cheng, MD Dr. Cheng has nothing to disclose.
Sheena K. Aurora, MD Dr. Aurora has received personal compensation for serving as an employee of Alzheimer's Association.
Josh Rowe Josh Rowe has received personal compensation for serving as an employee of Abbvie. Josh Rowe has received stock or an ownership interest from Abbvie.
Melissa Darsey, PA Melissa Darsey has a non-compensated relationship as a Clinical Research Assistant with Allergan that is relevant to Â鶹´«Ã½Ó³»­ interests or activities.
Todd J. Schwedt, MD, FÂ鶹´«Ã½Ó³»­ Dr. Schwedt has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Lundbeck. The institution of Dr. Schwedt has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Abbvie. Dr. Schwedt has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Salvia. Dr. Schwedt has or had stock in Nocira.Dr. Schwedt has or had stock in Allevalux. The institution of Dr. Schwedt has received research support from National Institutes of Health. The institution of Dr. Schwedt has received research support from United States Department of Defense. The institution of Dr. Schwedt has received research support from Patient Centered Outcomes Research Institute. The institution of Dr. Schwedt has received research support from Henry Jackson Foundation. The institution of Dr. Schwedt has received research support from Pfizer. The institution of Dr. Schwedt has received research support from National Headache Foundation. The institution of Dr. Schwedt has received research support from American Heart Association. The institution of Dr. Schwedt has received research support from AbbVie. The institution of Dr. Schwedt has received research support from Flinn Foundation. Dr. Schwedt has received intellectual property interests from a discovery or technology relating to health care. Dr. Schwedt has received intellectual property interests from a discovery or technology relating to health care. Dr. Schwedt has received intellectual property interests from a discovery or technology relating to health care. Dr. Schwedt has received intellectual property interests from a discovery or technology relating to health care. Dr. Schwedt has received publishing royalties from a publication relating to health care.
Chelsea Leroue Chelsea Leroue has received personal compensation for serving as an employee of Biohaven Pharmaceuticals.
Peter Goadsby, MD, PhD, FRS Dr. Goadsby has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Abbvie. Dr. Goadsby has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Teva Pharmaceuticals. Dr. Goadsby has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Lundbeck. Dr. Goadsby has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Satsuma. Dr. Goadsby has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Pfizer. Dr. Goadsby has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Shiratronics. Dr. Goadsby has received personal compensation in the range of $500-$4,999 for serving as a Consultant for CoolTech LLC. Dr. Goadsby has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Linpharma. Dr. Goadsby has received personal compensation in the range of $500-$4,999 for serving as a Consultant for PureTech Health LLC. Dr. Goadsby has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Kallyope. Dr. Goadsby has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Seaport Therapeutics. Dr. Goadsby has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Dr Reddy's. Dr. Goadsby has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Orion Pharma. Dr. Goadsby has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Ipsen. Dr. Goadsby has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Massachusetts Medical Society. The institution of Dr. Goadsby has received research support from NIHR. Dr. Goadsby has received publishing royalties from a publication relating to health care. Dr. Goadsby has received publishing royalties from a publication relating to health care. Dr. Goadsby has a non-compensated relationship as a Trustee with Migraine Trust that is relevant to Â鶹´«Ã½Ó³»­ interests or activities. Dr. Goadsby has a non-compensated relationship as a Trustee with Organisation for Understanding Cluster Headache (UK) that is relevant to Â鶹´«Ã½Ó³»­ interests or activities.
Evan Popoff No disclosure on file
Swathi Beladakere Ramaswamy, MD Dr. Beladakere Ramaswamy has nothing to disclose.
Mia T. Minen, MD, FÂ鶹´«Ã½Ó³»­ The institution of Dr. Minen has received research support from NIH. Dr. Minen has received intellectual property interests from a discovery or technology relating to health care. Dr. Minen has received personal compensation in the range of $500-$4,999 for serving as a First Contact-Primary Care Advisory Board Member with American Headache Society . Dr. Minen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for PCORI grant on migraine evidence based map for stakeholders with ECRI .
Jonathan Cheponis, MD Dr. Cheponis has nothing to disclose.
Diane L. Amend, PhD No disclosure on file
Roger Cady, MD Dr. Cady has received personal compensation for serving as an employee of Lundbeck. Dr. Cady has stock in Alder Biopharmaceutical.
Judith Krikke Judith Krikke has received personal compensation for serving as an employee of Eli Lilly and Company.
Camilo R. Gomez, MD, FÂ鶹´«Ã½Ó³»­ Dr. Gomez has nothing to disclose.
David W. Dodick, MD, FÂ鶹´«Ã½Ó³»­ Dr. Dodick has received personal compensation for serving as an employee of Mayo Clinic. Dr. Dodick has received personal compensation for serving as an employee of Atria Health. Dr. Dodick has received personal compensation for serving as an employee of Thomas Jefferson University . Dr. Dodick has received personal compensation for serving as an employee of Norwegian University of Science and Technology. Dr. Dodick has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Amgen. Dr. Dodick has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Allergan. Dr. Dodick has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Abbvie. Dr. Dodick has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biohaven. Dr. Dodick has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biopharm Communications. Dr. Dodick has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Lundbeck. Dr. Dodick has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Eli Lilly. Dr. Dodick has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Teva. Dr. Dodick has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Inside Practice Australia. Dr. Dodick has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Clinical Â鶹´«Ã½Ó³»­ Alliance. Dr. Dodick has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Genentech. Dr. Dodick has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Headache Cooperative of the Pacific . Dr. Dodick has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Medica Communications. Dr. Dodick has received personal compensation in the range of $500-$4,999 for serving as a Consultant for MJ Healthcare. Dr. Dodick has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Nocira. Dr. Dodick has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Praxis. Dr. Dodick has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Revance . Dr. Dodick has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Synapse Medical Communications. Dr. Dodick has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Vector Psychometrics. Dr. Dodick has received personal compensation in the range of $0-$499 for serving as a Consultant for Ayya Biosciences. Dr. Dodick has received personal compensation in the range of $0-$499 for serving as a Consultant for Theranica. Dr. Dodick has received personal compensation in the range of $100,000-$499,999 for serving as a Consultant for Atria. Dr. Dodick has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for WebMD. Dr. Dodick has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Thomas Jefferson University. Dr. Dodick has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Medforce. Dr. Dodick has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Precision HEOR. Dr. Dodick has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Genentech. Dr. Dodick has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Canadian Headache Society. Dr. Dodick has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Headache Cooperative of New England. Dr. Dodick has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Amgen Japan. Dr. Dodick has received personal compensation in the range of $0-$499 for serving as an officer or member of the Board of Directors for KingDevick Technologies. Dr. Dodick has received personal compensation in the range of $1,000,000+ for serving as an officer or member of the Board of Directors for Precon Health. Dr. Dodick has received personal compensation in the range of $0-$499 for serving as an officer or member of the Board of Directors for Ontologics. Dr. Dodick has received personal compensation in the range of $0-$499 for serving as an officer or member of the Board of Directors for Matterhorn. Dr. Dodick has received personal compensation in the range of $0-$499 for serving as an officer or member of the Board of Directors for Axon Therapeutics. Dr. Dodick has received personal compensation in the range of $0-$499 for serving as an officer or member of the Board of Directors for Cephalgia Group. Dr. Dodick has stock in Healint. Dr. Dodick has stock in Theranica. Dr. Dodick has stock in Aural Analytics . Dr. Dodick has stock in Epien. Dr. Dodick has stock in Matterhorn. Dr. Dodick has stock in Ontologics. Dr. Dodick has stock in Precon Health. Dr. Dodick has stock in King Devick Technologies. Dr. Dodick has stock in Nocira. Dr. Dodick has stock in Exsano. Dr. Dodick has stock in Palion. Dr. Dodick has stock in AYYA Biosciences. Dr. Dodick has stock in Perfood. Dr. Dodick has stock in Cephalgia Group. Dr. Dodick has stock in Atria Health. Dr. Dodick has stock in Man and Science. Dr. Dodick has stock in Eigenlyfe. An immediate family member of Dr. Dodick has stock in ScotiaLyfe. Dr. Dodick has stock in Axon Therapeutics. The institution of Dr. Dodick has received research support from Department of Defense. The institution of Dr. Dodick has received research support from Patient Centered Outcomes Research Institute. The institution of Dr. Dodick has received research support from Henry Jackson Foundation. Dr. Dodick has received intellectual property interests from a discovery or technology relating to health care. Dr. Dodick has received intellectual property interests from a discovery or technology relating to health care. Dr. Dodick has received intellectual property interests from a discovery or technology relating to health care. Dr. Dodick has received publishing royalties from a publication relating to health care. Dr. Dodick has received publishing royalties from a publication relating to health care. Dr. Dodick has received publishing royalties from a publication relating to health care. Dr. Dodick has a non-compensated relationship as a Chair with American Brain Foundation that is relevant to Â鶹´«Ã½Ó³»­ interests or activities. Dr. Dodick has a non-compensated relationship as a Committee member/Course Director with Â鶹´«Ã½Ó³»­ that is relevant to Â鶹´«Ã½Ó³»­ interests or activities. Dr. Dodick has a non-compensated relationship as a Chair/Immediate Past Chair with American Migraine Foundation that is relevant to Â鶹´«Ã½Ó³»­ interests or activities. Dr. Dodick has a non-compensated relationship as a Chair Global Patient Advocacy Coalition with International Headache Society that is relevant to Â鶹´«Ã½Ó³»­ interests or activities.
Emmanuelle Schindler, MD, PhD Dr. Schindler has received intellectual property interests from a discovery or technology relating to health care.
H. C. Diener, MD, FÂ鶹´«Ã½Ó³»­ Dr. Diener has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Lundbeck. Dr. Diener has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for TEVA. Dr. Diener has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Lundbeck. Dr. Diener has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Springer. Dr. Diener has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Thieme. The institution of Dr. Diener has received research support from German Research Council.
Benjamin M. Frishberg, MD, FÂ鶹´«Ã½Ó³»­ Dr. Frishberg has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for BMS. Dr. Frishberg has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for novartis. Dr. Frishberg has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for genentech. Dr. Frishberg has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Lilly. Dr. Frishberg has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Roche. Dr. Frishberg has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Allergan. Dr. Frishberg has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Lundbeck. Dr. Frishberg has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Novartis. Dr. Frishberg has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for BMS. Dr. Frishberg has received personal compensation in the range of $50,000-$99,999 for serving on a Speakers Bureau for Biogen. Dr. Frishberg has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Sanofi. Dr. Frishberg has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Biohaven. Dr. Frishberg has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Viela-Bio. Dr. Frishberg has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Horizon. Dr. Frishberg has received personal compensation in the range of $5,000-$9,999 for serving as an officer or member of the Board of Directors for Headache Cooperative of the Pacific. Dr. Frishberg has a non-compensated relationship as a Delegate with AMA that is relevant to Â鶹´«Ã½Ó³»­ interests or activities.
Ali Ezzati, MD The institution of Dr. Ezzati has received research support from NIA. The institution of Dr. Ezzati has received research support from Alzheimer's Association. The institution of Dr. Ezzati has received research support from Cure Alzheimer's Fund.
Philip Wang Mr. Wang has nothing to disclose.
Richard Wenzel Richard Wenzel has received personal compensation for serving as an employee of Eli Lilly. Richard Wenzel has received stock or an ownership interest from Eli Lilly.
Kiana Moussavi, MD Dr. Moussavi has nothing to disclose.
Gina Dumkrieger, PhD Gina Dumkrieger has received personal compensation for serving as an employee of Mayo Clinic. The institution of Gina Dumkrieger has received research support from NIH. The institution of Gina Dumkrieger has received research support from DOD. The institution of Gina Dumkrieger has received research support from AMGEN.
Ahmed Abbas, MD Dr. Abbas has nothing to disclose.
Hannah Shapiro, MD The institution of Dr. Shapiro has received research support from Pfizer. The institution of Dr. Shapiro has received research support from PCORI.
Bradley J. Katz, MD, PhD Bradley J. Katz, MD, PhD has received personal compensation in the range of $500-$4,999 for serving as an officer or member of the Board of Directors for axon optics, LLC. Bradley J. Katz, MD, PhD has received personal compensation in the range of $10,000-$49,999 for serving as an Expert Witness for self employed. Bradley J. Katz, MD, PhD has received stock or an ownership interest from Pfizer. Bradley J. Katz, MD, PhD has received intellectual property interests from a discovery or technology relating to health care.
Laur Marius Birlea, MD, FÂ鶹´«Ã½Ó³»­ Dr. Birlea has nothing to disclose.
Maria A. Rocca Maria Assunta Rocca has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biogen, Bristol Myers Squibb, Eli Lilly, Janssen, Roche. Maria Assunta Rocca has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for AstraZaneca, Biogen, Bristol Myers Squibb, Bromatech, Celgene, Genzyme, Horizon Therapeutics Italy, Merck Serono SpA, Novartis, Roche, Sanofi and Teva. The institution of Maria Assunta Rocca has received research support from MS Society of Canada, the Italian Ministry of Health, the Italian Ministry of University and Research, and Fondazione Italiana Sclerosi Multipla.
Negar Moheb, MD Dr. Moheb has nothing to disclose.
Bert B. Vargas, MD, FÂ鶹´«Ã½Ó³»­ Dr. Vargas has received personal compensation for serving as an employee of Lilly USA. Dr. Vargas has received personal compensation in the range of $500-$4,999 for serving as a Consultant for National Football League. Dr. Vargas has or had stock in Eli Lilly. An immediate family member of Dr. Vargas has or had stock in Pfizer.Dr. Vargas has received personal compensation in the range of $500-$4,999 for serving as a Unaffiliated Neurotrauma Consultant with National Football League. Dr. Vargas has received personal compensation in the range of $10,000-$49,999 for serving as a Neurotrauma Consultant with National Association for Stock Car Auto Racing.
Lynn Do, PharmD Dr. Do has received personal compensation for serving as an employee of Eli Lilly.
Karen Carr Karen Carr has received stock or an ownership interest from Teva Pharmaceuticals. An immediate family member of Karen Carr has received stock or an ownership interest from Genentech.
Andres A. Arciniegas, MD, MSHA, MSHI Dr. Arciniegas has nothing to disclose.
Katherine Ross Katherine Ross has nothing to disclose.
Danielle D. DeSouza, PhD Dr. DeSouza has received personal compensation for serving as an employee of Acacia Clinics. Dr. DeSouza has stock in Acacia Clinics.
Cherisse Mecham Ms. Mecham has nothing to disclose.
Nazia Karsan, MBBS, PhD Dr. Karsan has nothing to disclose.
Lauren D. Strauss, DO Dr. Strauss has a non-compensated relationship as a Secretary with Southern Headache Society that is relevant to Â鶹´«Ã½Ó³»­ interests or activities.
Dennique Khanns Dennique Khanns has nothing to disclose.
Mason D. Dyess, DO Dr. Dyess has nothing to disclose.
Ashhar Ali, DO, FÂ鶹´«Ã½Ó³»­ Dr. Ali has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Pfizer. Dr. Ali has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Ebsco.
Aubrey Adams, PhD Dr. Manack Adams has received personal compensation for serving as an employee of Abbvie. Dr. Manack Adams has stock in Abbvie.
Dawn C. Buse, PhD Dr. Buse has received personal compensation for serving as an employee of Vector Psychometric Group. Dr. Buse has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Abbvie-Allergan. Dr. Buse has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Amgen. Dr. Buse has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Lilly. Dr. Buse has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Lundbeck. Dr. Buse has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Teva. Dr. Buse has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Theranicsa. Dr. Buse has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Lilly. Dr. Buse has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Abbvie-Allergan. Dr. Buse has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Lundbeck. Dr. Buse has received personal compensation in the range of $0-$499 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Current Pain and Headache Reports. The institution of Dr. Buse has received research support from Amgen. The institution of Dr. Buse has received research support from FDA. The institution of Dr. Buse has received research support from National Headache Foundation.
Juanzhi Fang Juanzhi Fang has received personal compensation for serving as an employee of Novartis Pharmaceutical. Juanzhi Fang has received stock or an ownership interest from Novartis Pharmaceutical.
Hsiangkuo Yuan, MD, PhD An immediate family member of Dr. Yuan has received personal compensation for serving as an employee of Merck. Dr. Yuan has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Pfizer. Dr. Yuan has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Abbvie. Dr. Yuan has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Pfizer. Dr. Yuan has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Salvia. Dr. Yuan has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Cerenovous. Dr. Yuan has received personal compensation in the range of $0-$499 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Regional Anesthesia and Pain Medicine. Dr. Yuan has received personal compensation in the range of $0-$499 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Current Headache and Pain Reports. Dr. Yuan has received personal compensation in the range of $0-$499 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for MedLink Neurology. Dr. Yuan has received personal compensation in the range of $0-$499 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Cephalalgia. The institution of Dr. Yuan has received research support from NIH. The institution of Dr. Yuan has received research support from American Headache Society. The institution of Dr. Yuan has received research support from Pfizer. Dr. Yuan has received publishing royalties from a publication relating to health care. Dr. Yuan has received publishing royalties from a publication relating to health care. Dr. Yuan has received personal compensation in the range of $500-$4,999 for serving as a Grant reviewer with NIH. Dr. Yuan has received personal compensation in the range of $10,000-$49,999 for serving as a Invited speaker with Chinese Stroke Association.
Michael L. Reed, PhD The institution of Dr. Reed has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Eli Lilly. The institution of Dr. Reed has received research support from Allergan. The institution of Dr. Reed has received research support from Dr Reddy's Labs/Promius. The institution of Dr. Reed has received research support from Allay Lamp. Dr. Reed has a non-compensated relationship as a Research Analyst with National Headache Foundation that is relevant to Â鶹´«Ã½Ó³»­ interests or activities.
Jordan Lateiner, MS, MBA Mr. Lateiner has received personal compensation for serving as an employee of Abbvie. Mr. Lateiner has received stock or an ownership interest from Abbvie.
Jennifer W. McVige, MD, FÂ鶹´«Ã½Ó³»­ Dr. McVige has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Abbvie. Dr. McVige has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for AbbVie. Dr. McVige has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for UCB. Dr. McVige has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Neurelis. The institution of Dr. McVige has received research support from Amgen. The institution of Dr. McVige has received research support from Eli Lily. The institution of Dr. McVige has received research support from Biohaven/Pfizer. The institution of Dr. McVige has received research support from Lundbeck. The institution of Dr. McVige has received research support from Dent Family Foundation. The institution of Dr. McVige has received research support from Abbvie. The institution of Dr. McVige has received research support from Teva. The institution of Dr. McVige has received research support from Theranica. Dr. McVige has a non-compensated relationship as a Neurology Board with UCNS that is relevant to Â鶹´«Ã½Ó³»­ interests or activities. Dr. McVige has a non-compensated relationship as a Board Exam Board Member with ABPN that is relevant to Â鶹´«Ã½Ó³»­ interests or activities.
Noah Rosen, MD, FÂ鶹´«Ã½Ó³»­ Dr. Rosen has received personal compensation for serving as an employee of Northwell Health. An immediate family member of Dr. Rosen has received personal compensation for serving as an employee of New York University. Dr. Rosen has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Allergan/ Abbvie. Dr. Rosen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Lundbeck. Dr. Rosen has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Pfizer . Dr. Rosen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Amneal. Dr. Rosen has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Allergan/ Abbvie. Dr. Rosen has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Pfizer. Dr. Rosen has received personal compensation in the range of $0-$499 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Springer.
Daniel Krashin, MD Dr. Krashin has nothing to disclose.
Robert A. Nicholson, PhD Dr. Nicholson has received personal compensation for serving as an employee of Eli Lilly & Company. Dr. Nicholson has stock in Eli Lilly & Company. Dr. Nicholson has received intellectual property interests from a discovery or technology relating to health care.
Maurice Driessen No disclosure on file
Joanne Kacperski, MD Dr. Kacperski has nothing to disclose.
Kelsey Satterly Kelsey Satterly has received personal compensation for serving as an employee of Impel NeuroPharma . Kelsey Satterly has received intellectual property interests from a discovery or technology relating to health care.
Deborah I. Friedman, MD, MPH, FÂ鶹´«Ã½Ó³»­ Dr. Friedman has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Lundbeck. Dr. Friedman has received personal compensation in the range of $50,000-$99,999 for serving as a Consultant for Pfizer. Dr. Friedman has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Axsome. Dr. Friedman has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Amneal. Dr. Friedman has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Abbvie. Dr. Friedman has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Axsone. Dr. Friedman has received personal compensation in the range of $50,000-$99,999 for serving on a Speakers Bureau for Pfizer. Dr. Friedman has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for MedLink Neurology . Dr. Friedman has a non-compensated relationship as a Program Co-Chair, Scottsdale Headache Symposium with American Headache Society that is relevant to Â鶹´«Ã½Ó³»­ interests or activities. Dr. Friedman has a non-compensated relationship as a Medical Advisor with Spinal CSF Leak Foundation that is relevant to Â鶹´«Ã½Ó³»­ interests or activities. Dr. Friedman has a non-compensated relationship as a President-elect, Board of Directors with Southern Headache Society that is relevant to Â鶹´«Ã½Ó³»­ interests or activities.
Andreja Packard, MD, PhD Dr. Packard has nothing to disclose.
Narayan R. Kissoon, MD Dr. Kissoon has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Vertex Pharmaceuticals. The institution of Dr. Kissoon has received research support from Nevro Corporation. The institution of Dr. Kissoon has received research support from Novo Nordisc Foundation. The institution of Dr. Kissoon has received research support from Shiratronics. Dr. Kissoon has received publishing royalties from a publication relating to health care.
Fawad A. Khan, MD The institution of Dr. Khan has received research support from Amgen .
Florencia Wainberg, MD Dr. Wainberg has nothing to disclose.
Nico Pannacciulli Nico Pannacciulli has received personal compensation for serving as an employee of Amgen. Nico Pannacciulli has received stock or an ownership interest from Amgen.
Erin G. Doty, MD Dr. Doty has received personal compensation for serving as an employee of Eli Lilly and Company, USA. Dr. Doty has stock in Eli Lilly and Company, USA.
Ramiro G. Castro Apolo, MD Dr. Castro Apolo has nothing to disclose.
Tina Oakes Tina Oakes has received personal compensation for serving as an employee of Eli Lilly. Tina Oakes has received stock or an ownership interest from Eli Lilly.
Sunfa Cheng Sunfa Cheng has received personal compensation for serving as an employee of Amgen. Sunfa Cheng has received stock or an ownership interest from Amgen.
Morris Levin, MD, FÂ鶹´«Ã½Ó³»­ Dr. Levin has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Supernus, Upsher Smith, Biohaven, Revance, Percept, Theranica, Allergan, Alder, Currax. Dr. Levin has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Theranica. Dr. Levin has received personal compensation in the range of $500-$4,999 for serving as an officer or member of the Board of Directors for Headache Cooperative of the Pacific. Dr. Levin has received personal compensation in the range of $500-$4,999 for serving as an Expert Witness for Attorney . Dr. Levin has received stock or an ownership interest from Percept. Dr. Levin has received publishing royalties from a publication relating to health care.
Peter J. McAllister, MD, FÂ鶹´«Ã½Ó³»­ Dr. McAllister has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for pfizer. Dr. McAllister has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for lilly. Dr. McAllister has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for abbvie. Dr. McAllister has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for lundbeck.
Jan L. Brandes, MD Dr. Brandes has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Lundbeck. Dr. Brandes has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Lilly. Dr. Brandes has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Amgen. Dr. Brandes has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Lundbeck. Dr. Brandes has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Theranica. Dr. Brandes has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Teva. Dr. Brandes has received personal compensation in the range of $100,000-$499,999 for serving on a Speakers Bureau for Lilly. Dr. Brandes has received personal compensation in the range of $100,000-$499,999 for serving on a Speakers Bureau for Amgen. Dr. Brandes has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Lundbeck. Dr. Brandes has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Allergan. Dr. Brandes has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Teva. Dr. Brandes has received personal compensation in the range of $10,000-$49,999 for serving as an Expert Witness for Lewis Thomason. Dr. Brandes has received research support from Amgen. Dr. Brandes has received research support from Teva. Dr. Brandes has received research support from Allergan. Dr. Brandes has received research support from Biohaven. Dr. Brandes has a non-compensated relationship as a Board Member with National Headache Foundation that is relevant to Â鶹´«Ã½Ó³»­ interests or activities.
John H. Krege John H. Krege has received personal compensation for serving as an employee of Eli Lilly. John H. Krege has received stock or an ownership interest from Eli Lilly.
Holly Elser, MD, PhD Dr. Elser has nothing to disclose.
Vivienne Shen Vivienne Shen has received personal compensation for serving as an employee of Lundbeck.
Richard Reimer No disclosure on file
Jack D. Schim, MD, FÂ鶹´«Ã½Ó³»­ Dr. Schim has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Aeon, Abbvie, Amgen, Biohaven, electroCore, Impel, Lilly, Lundbeck, Novartis, Promius, Revance, Teva, Upsher-Smith. Dr. Schim has received personal compensation in the range of $100,000-$499,999 for serving on a Speakers Bureau for Allergan, Amgen, Biohaven, electroCore, Lilly, Lundbeck, Novartis, Promius, Teva, Theranica, Upsher-Smith.
Iftekhar Ahmed, MD, PC, FÂ鶹´«Ã½Ó³»­ Dr. Ahmed has nothing to disclose.
Katherine Sommer Katherine Sommer has received personal compensation for serving as an employee of AbbVie. Katherine Sommer has stock in AbbVie.
Mallikarjuna Rettiganti, PhD Dr. Rettiganti has received personal compensation for serving as an employee of Eli Lilly and Company. Dr. Rettiganti has received stock or an ownership interest from Eli Lilly and Company.
Pranav Gandhi Pranav Gandhi has received personal compensation for serving as an employee of AbbVie. Pranav Gandhi has stock in AbbVie Inc.
Niushen Zhang, MD Dr. Zhang has nothing to disclose.
Andrew H. Ahn, MD, PhD Dr. Ahn has received personal compensation for serving as an employee of Teva Pharmaceuticals.
Nitish Kumar, MD Dr. Kumar has nothing to disclose.
Karen Craig Karen Craig has received personal compensation for serving as an employee of Impel NeuroPharma.
Mirja Koch Mirja Koch has received personal compensation for serving as an employee of Novartis.
Daniela Salvemini No disclosure on file
Cynthia E. Armand, MD, FÂ鶹´«Ã½Ó³»­ Dr. Armand has received personal compensation in the range of $500-$4,999 for serving as a Consultant for CE Interactive. Dr. Armand has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Pfizer. Dr. Armand has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Pfizer. Dr. Armand has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for JAMA Neurology.
Tariq Hamid, MD Dr. Hamid has nothing to disclose.
Crystal Jicha, MD Dr. Jicha has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for LinPharma.
Carrie Carr Carrie Carr has nothing to disclose.
Helen Hochstetler, PharmD Helen Hochstetler, PharmD has received personal compensation for serving as an employee of Eli Lilly and Company. Helen Hochstetler, PharmD has received stock or an ownership interest from Eli Lilly and Company.
Christopher J. Bondoc, MD Dr. Bondoc has nothing to disclose.
Brad C. Klein, MD, MBA, FÂ鶹´«Ã½Ó³»­ Dr. Klein has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for AbbVie. Dr. Klein has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Eli Lilly and Company. Dr. Klein has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Lundbeck. Dr. Klein has received personal compensation in the range of $50,000-$99,999 for serving on a Speakers Bureau for AbbVie. Dr. Klein has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Lundbeck. Dr. Klein has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Axsome. The institution of Dr. Klein has received research support from AbbVie. Dr. Klein has received personal compensation in the range of $500-$4,999 for serving as a Shareholder with AppsbyDocs, LLC. Dr. Klein has a non-compensated relationship as a Chair, Practice Management Committee with American Headache Society that is relevant to Â鶹´«Ã½Ó³»­ interests or activities.
Robert Croop, MD Dr. Croop has received personal compensation for serving as an employee of Biohaven Pharmaceuticals, Inc. Dr. Croop has received personal compensation for serving as an employee of Pfizer Inc.. Dr. Croop has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Collima LLC. Dr. Croop has stock in Biohaven Pharmaceutical Holding Co Ltd. Dr. Croop has stock in Biohaven Ltd.. Dr. Croop has stock in Actio Biosciences, Inc. . Dr. Croop has received research support from Pfizer Inc. Dr. Croop has received intellectual property interests from a discovery or technology relating to health care. Dr. Croop has received intellectual property interests from a discovery or technology relating to health care.
Daniel Serrano, PhD Dr. Serrano has nothing to disclose.
Veronica A. Moreno Gomez, MD Dr. Moreno Gomez has nothing to disclose.
Muhammad Affan, MD Dr. Affan has nothing to disclose.
Mary Hopkins No disclosure on file
Louise Lombard Louise Lombard has received personal compensation for serving as an employee of Eli Lilly.
Nasser Mohammed, MBBS Dr. Mohammed has nothing to disclose.
Charlie Conway Charlie Conway has received personal compensation for serving as an employee of Biohaven Pharmaceuticals Inc. Charlie Conway has received stock or an ownership interest from Biohaven Pharmaceuticals.
Charles Iaconangelo, PhD Dr. Iaconangelo has received personal compensation for serving as an employee of Open Health Group.
Christina Sun-Edelstein, MD Dr. Sun-Edelstein has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Teva. Dr. Sun-Edelstein has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Eli Lilly. Dr. Sun-Edelstein has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Lundbeck. Dr. Sun-Edelstein has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Teva. Dr. Sun-Edelstein has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Eli Lilly. Dr. Sun-Edelstein has received publishing royalties from a publication relating to health care.
Frank R. Berenson, MD Dr. Berenson has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Upsher smith. Dr. Berenson has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biohaven. Dr. Berenson has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Teva. Dr. Berenson has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Lilly. Dr. Berenson has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Biohaven. Dr. Berenson has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Allergan. Dr. Berenson has received personal compensation in the range of $10,000-$49,999 for serving as an Expert Witness for Atlanta Headache Specialists .
José H. Posas, MD, FÂ鶹´«Ã½Ó³»­ Dr. Posas has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Pfizer. Dr. Posas has or had stock in Dane Health.Dr. Posas has or had stock in Brainscope.Dr. Posas has a non-compensated relationship as a Advisor with Dane Health that is relevant to Â鶹´«Ã½Ó³»­ interests or activities. Dr. Posas has a non-compensated relationship as a Lecturer with Concussion Corner Academy that is relevant to Â鶹´«Ã½Ó³»­ interests or activities. Dr. Posas has a non-compensated relationship as a Advisor with Brainscope that is relevant to Â鶹´«Ã½Ó³»­ interests or activities.
Paul B. Rizzoli, MD, FÂ鶹´«Ã½Ó³»­ Dr. Rizzoli has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Axsome. Dr. Rizzoli has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Theranica. Dr. Rizzoli has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Axsome. Dr. Rizzoli has received personal compensation in the range of $10,000-$49,999 for serving as an officer or member of the Board of Directors for Headache Cooperative of New England. Dr. Rizzoli has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Harvard Health Publishing. The institution of Dr. Rizzoli has received research support from Abbvie. Dr. Rizzoli has received publishing royalties from a publication relating to health care.
Fayyaz Ahmed, MD, FRCP Dr. Ahmed has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for allergan.
Catherine D. Chong, PhD, FÂ鶹´«Ã½Ó³»­ Dr. Chong has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for HCOP.
Shawn M. Ferger, RN Mr. Ferger has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Acadia Pharmaceuticals. Mr. Ferger has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Allergan Pharmaceuticals.
Kory Schuh Kory Schuh has received personal compensation for serving as an employee of Eli Lilly and Company.
Poonam Bansal, MD Dr. Bansal has nothing to disclose.
Vladimir Coric Vladimir Coric has received personal compensation for serving as an employee of Biohaven. Vladimir Coric has received personal compensation in the range of $1,000,000+ for serving as an officer or member of the Board of Directors for Bioahven. Vladimir Coric has stock in Biohaven. Vladimir Coric has received intellectual property interests from a discovery or technology relating to health care.
Yohannes W. Woldeamanuel, MD Dr. Woldeamanuel has received personal compensation in the range of $0-$499 for serving as a Consultant for Atheneum. Dr. Woldeamanuel has received personal compensation in the range of $0-$499 for serving as a Consultant for Research Square. The institution of Dr. Woldeamanuel has received research support from NINDS. Dr. Woldeamanuel has a non-compensated relationship as a Chief Medical Officer, Co-Founder with Ex-Amplify Therapeutics that is relevant to Â鶹´«Ã½Ó³»­ interests or activities. Dr. Woldeamanuel has a non-compensated relationship as a Adjunct Faculty with Arizona State University that is relevant to Â鶹´«Ã½Ó³»­ interests or activities. Dr. Woldeamanuel has a non-compensated relationship as a Founder & Consultant with Advanced Clinical & Research Center that is relevant to Â鶹´«Ã½Ó³»­ interests or activities.
Faisal A. Ibrahim, MD Dr. Ibrahim has nothing to disclose.
Sutapa Ray, PhD Dr. Ray has received personal compensation for serving as an employee of Impel Pharmaceuticals. Dr. Ray has stock in Impel Pharmaceuticals.
Tejas R. Mehta, MD Dr. Mehta has nothing to disclose.
Anders Ettrup Anders Ettrup has received personal compensation for serving as an employee of H. Lundbeck A/S.
Kendra K. Davis Ms. Davis has nothing to disclose.
Ankita Ghosh, MD Dr. Ghosh has nothing to disclose.
Monica P. Mallampalli, PhD Monica Mallampalli has nothing to disclose.
Ahmad Abdrabboh, PharmD Ahmad Abdrabboh, PharmD has received personal compensation for serving as an employee of Novartis. Ahmad Abdrabboh, PharmD has received stock or an ownership interest from Novartis.
Anusha Badveli, DM Dr. Badveli has nothing to disclose.
Uwe Reuter Uwe Reuter has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Allergan. Uwe Reuter has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Abbvie. Uwe Reuter has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Novartis. Uwe Reuter has received personal compensation in the range of $500-$4,999 for serving as a Consultant for TEVA. Uwe Reuter has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Liily Deutschland. Uwe Reuter has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Amgen. Uwe Reuter has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Allergan/Abbvie. Uwe Reuter has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Lilly. Uwe Reuter has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for TEVA. Uwe Reuter has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. The institution of Uwe Reuter has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Lundbeck. Uwe Reuter has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Allergan. Uwe Reuter has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Lilly. Uwe Reuter has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Medscape . Uwe Reuter has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Novartis. Uwe Reuter has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for StreaMEdUp. Uwe Reuter has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Teva. The institution of Uwe Reuter has received research support from Novartis.
Gary D. Berman, MD Dr. Berman has received personal compensation for serving as an employee of Clinical Research Institute. Dr. Berman has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Amgen. Dr. Berman has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Alder. Dr. Berman has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Amgen. Dr. Berman has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Lilly. Dr. Berman has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Teva. Dr. Berman has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Allergen. Dr. Berman has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Biohaven.
Lester Y. Leung, MD Dr. Leung has received research support from NIH.
Niranjan N. Singh, MD, FÂ鶹´«Ã½Ó³»­ Dr. Singh has nothing to disclose.
Brian Grosberg, MD Dr. Grosberg has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Amgen. Dr. Grosberg has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Theranica. Dr. Grosberg has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Abbvie. Dr. Grosberg has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Linpharma pharmaceuticals. Dr. Grosberg has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Amgen. Dr. Grosberg has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Theranica . Dr. Grosberg has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Biohaven. Dr. Grosberg has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Abbvie. Dr. Grosberg has stock in Theranica. The institution of Dr. Grosberg has received research support from Theranica. The institution of Dr. Grosberg has received research support from Amgen. The institution of Dr. Grosberg has received research support from Abbvie. The institution of Dr. Grosberg has received research support from Eli Lilly. The institution of Dr. Grosberg has received research support from Teva. The institution of Dr. Grosberg has received research support from Neurolief. Dr. Grosberg has received publishing royalties from a publication relating to health care.
Kathleen B. Digre, MD, FÂ鶹´«Ã½Ó³»­ Dr. Digre has received personal compensation in the range of $0-$499 for serving as an officer or member of the Board of Directors for American Headache Society. The institution of Dr. Digre has received personal compensation in the range of $0-$499 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Journal of Neuro-ophthalmology. The institution of Dr. Digre has received personal compensation in the range of $0-$499 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Utah Womens Health Review. Dr. Digre has received intellectual property interests from a discovery or technology relating to health care. Dr. Digre has received intellectual property interests from a discovery or technology relating to health care. Dr. Digre has received intellectual property interests from a discovery or technology relating to health care. Dr. Digre has received publishing royalties from a publication relating to health care. Dr. Digre has received publishing royalties from a publication relating to health care.
Brian Koo, MD Dr. Koo has received personal compensation in the range of $500-$4,999 for serving as a Consultant for American Regent. Dr. Koo has received personal compensation in the range of $5,000-$9,999 for serving as an Expert Witness for Speckhals Law. The institution of Dr. Koo has received research support from Department of Defense.
Ami Cuneo, MD Dr. Cuneo has nothing to disclose.
Xiaoping Ning Ms. Ning has received personal compensation for serving as an employee of Teva Pharmaceutical . Ms. Ning has received personal compensation for serving as an employee of Teva Pharmaceutical.
Michael Seminerio Michael Seminerio has received personal compensation for serving as an employee of AbbVie.
Jelena M. Pavlovic, MD, PhD Dr. Pavlovic has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Ipsen. Dr. Pavlovic has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Abbvie.
Ammar Tarabichi, MD Dr. Tarabichi has nothing to disclose.
Kathryn H. Keller, PharmD Kathryn H. Keller, PharmD has received personal compensation for serving as an employee of Biohaven Pharmaceuticals. Kathryn H. Keller, PharmD has received stock or an ownership interest from Biohaven Pharmaceuticals.
Annika Ehrlich, DNP, FNP-C, AQH, CNRN Dr. Ehrlich has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Abbvie Pharmaceuticals. Dr. Ehrlich has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Pharmamark. Dr. Ehrlich has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Focus MedEd. Dr. Ehrlich has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Pfizer. Dr. Ehrlich has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Theranica. Dr. Ehrlich has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Lundbeck. Dr. Ehrlich has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for eNeura. Dr. Ehrlich has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Abbvie. Dr. Ehrlich has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Axome Therapeutics. Dr. Ehrlich has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Abbvie. Dr. Ehrlich has received personal compensation in the range of $5,000-$9,999 for serving as an officer or member of the Board of Directors for Headache Cooperative of the Pacific. Dr. Ehrlich has received personal compensation in the range of $500-$4,999 for serving as an officer or member of the Board of Directors for Neurology Advanced Practice Providers. Dr. Ehrlich has a non-compensated relationship as a Board President with Alliance for Headache Disorders Advocacy that is relevant to Â鶹´«Ã½Ó³»­ interests or activities. Dr. Ehrlich has a non-compensated relationship as a Board President with The Headache Alliance that is relevant to Â鶹´«Ã½Ó³»­ interests or activities. Dr. Ehrlich has a non-compensated relationship as a Advanced Practice Provider Board Liaison with American Headache Society that is relevant to Â鶹´«Ã½Ó³»­ interests or activities.
Liqi Shu, MD Dr. Shu has nothing to disclose.
Andrew D. Hershey, MD, PhD, FAHS, FÂ鶹´«Ã½Ó³»­ The institution of Dr. Hershey has received personal compensation in the range of $0-$499 for serving as a Consultant for Amgen. The institution of Dr. Hershey has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Lundbeck. The institution of Dr. Hershey has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Supernus. The institution of Dr. Hershey has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Upsher-Smith. The institution of Dr. Hershey has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Teva. The institution of Dr. Hershey has received research support from Amgen. The institution of Dr. Hershey has received research support from NIH, NINDS. The institution of Dr. Hershey has received research support from Bioahaven. The institution of Dr. Hershey has received research support from Upsher-Smith. Dr. Hershey has received publishing royalties from a publication relating to health care.
Julie Roth, MD, FÂ鶹´«Ã½Ó³»­ Dr. Roth has nothing to disclose.
Stephen Thompson No disclosure on file
Carrie Dougherty, MD, FÂ鶹´«Ã½Ó³»­ Dr. Dougherty has received personal compensation in the range of $500-$4,999 for serving as a Consultant for AbbVie. Dr. Dougherty has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Eli Lilly. Dr. Dougherty has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Lundbeck. Dr. Dougherty has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Satsuma. Dr. Dougherty has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Axsome. The institution of Dr. Dougherty has received research support from Eli Lilly and Co. The institution of Dr. Dougherty has received research support from AbbVie. The institution of Dr. Dougherty has received research support from Axsome. The institution of Dr. Dougherty has received research support from Lundbeck.
Sachin M. Bhagavan, MD Dr. Bhagavan has nothing to disclose.
Amy Grinberg, PhD The institution of Amy Grinberg has received research support from Department of Veteran Affairs.
Elizabeth Seng, PhD Dr. Seng has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Abbvie. Dr. Seng has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Theranica. Dr. Seng has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Pfizer. The institution of Dr. Seng has received research support from NCCIH. Dr. Seng has received research support from Cystic Fibrosis Foundation. The institution of Dr. Seng has received research support from American Heart Association.
Hema Viswanathan Ms. Viswanathan has received personal compensation for serving as an employee of Allergan plc. Ms. Viswanathan has received personal compensation for serving as an employee of Precision Medicine Group. Ms. Viswanathan has received stock or an ownership interest from Allergan plc. Ms. Viswanathan has received stock or an ownership interest from Precision Medicine Group.
Patricia Pozo-Rosich, MD, PhD Dr. Pozo-Rosich has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for AbbVie. Dr. Pozo-Rosich has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Teva Pharmaceuticals. Dr. Pozo-Rosich has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Lundbeck. Dr. Pozo-Rosich has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Pfizer. Dr. Pozo-Rosich has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Organon. Dr. Pozo-Rosich has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Dr. Reddy's. Dr. Pozo-Rosich has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Sociedad Española Neurologia.
Jason J. Sico, MD, FÂ鶹´«Ã½Ó³»­ Dr. Sico has nothing to disclose.
Samar F. Ahmed, MD Dr. Ahmed has nothing to disclose.
Yoshimi Hisamoto, MD Dr. Hisamoto has nothing to disclose.
Rashmi B. Halker Singh, MD, FÂ鶹´«Ã½Ó³»­ Dr. Halker Singh has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Pfizer. Dr. Halker Singh has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for AbbVie. Dr. Halker Singh has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Lundbeck. Dr. Halker Singh has received personal compensation in the range of $0-$499 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Current Neurology & Neuroscience Reports. Dr. Halker Singh has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Headache Journal. Dr. Halker Singh has received publishing royalties from a publication relating to health care. Dr. Halker Singh has received personal compensation in the range of $5,000-$9,999 for serving as a CME speaker with Pri-med. Dr. Halker Singh has received personal compensation in the range of $500-$4,999 for serving as a CME speaker with Medscape.
Mika Komori Mika Komori has received personal compensation for serving as an employee of Eli Lilly K.K..
Mario F. Peres, MD Dr. Peres has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Eurofarma. Dr. Peres has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Eli Lilly. Dr. Peres has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Libbs. Dr. Peres has received research support from CNPq. Dr. Peres has received research support from Allergan.
Paola Valsasina Paola Valsasina has nothing to disclose.
Raghavendra Vasudeva, PhD Dr. Vasudeva has received personal compensation for serving as an employee of Lilly. Dr. Vasudeva has stock in Lilly.
Rogelio Dominguez-Moreno, MD Dr. Dominguez-Moreno has nothing to disclose.
Wojciech Gryc, MD Dr. Gryc has nothing to disclose.
Sarah M. Bobker, MD Dr. Bobker has nothing to disclose.
Aidan Levine Mr. Levine has received research support from University of Arizona MD/PhD Program.
Robert Cowan, MD, FÂ鶹´«Ã½Ó³»­ Dr. Cowan has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Lundbeck. Dr. Cowan has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Teva. Dr. Cowan has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Abbvie. Dr. Cowan has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Lilly. Dr. Cowan has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biohaven. Dr. Cowan has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for lundbeck. Dr. Cowan has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for biohavenn. Dr. Cowan has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Abbviie. Dr. Cowan has stock in Percept. Dr. Cowan has received intellectual property interests from a discovery or technology relating to health care. Dr. Cowan has received intellectual property interests from a discovery or technology relating to health care. Dr. Cowan has received publishing royalties from a publication relating to health care.
Stewart J. Tepper, MD Dr. Tepper has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Aeon. Dr. Tepper has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Abbvie. Dr. Tepper has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Amgen. Dr. Tepper has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Aruene. Dr. Tepper has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Atheneum. Dr. Tepper has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Axsome Therapeutics. Dr. Tepper has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Becker Pharmaceutical Consulting. Dr. Tepper has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Clearview Healhcare Partners. Dr. Tepper has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for CoolTech. Dr. Tepper has received personal compensation in the range of $500-$4,999 for serving as a Consultant for CRG. Dr. Tepper has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Decision Resources. Dr. Tepper has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Defined Health. Dr. Tepper has received personal compensation in the range of $500-$4,999 for serving as a Consultant for DRG. Dr. Tepper has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Eli Lilly. Dr. Tepper has received personal compensation in the range of $500-$4,999 for serving as a Consultant for ExpertConnect. Dr. Tepper has received personal compensation in the range of $500-$4,999 for serving as a Consultant for FCB Health. Dr. Tepper has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Fenix. Dr. Tepper has received personal compensation in the range of $500-$4,999 for serving as a Consultant for GLG. Dr. Tepper has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Guidepoint Global. Dr. Tepper has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Health Advances. Dr. Tepper has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Health Science Communications. Dr. Tepper has received personal compensation in the range of $500-$4,999 for serving as a Consultant for HMP Communications. Dr. Tepper has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Impel. Dr. Tepper has received personal compensation in the range of $500-$4,999 for serving as a Consultant for InteractiveForums. Dr. Tepper has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Keyquest. Dr. Tepper has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Krog and Partners. Dr. Tepper has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Lundbeck. Dr. Tepper has received personal compensation in the range of $500-$4,999 for serving as a Consultant for M3 Global Research. Dr. Tepper has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Magnolia Innovation. Dr. Tepper has received personal compensation in the range of $500-$4,999 for serving as a Consultant for MJH Holdings. Dr. Tepper has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Neurolief. Dr. Tepper has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novartis. Dr. Tepper has received personal compensation in the range of $500-$4,999 for serving as a Consultant for P Value Communications. Dr. Tepper has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Pain Insights Inc. Dr. Tepper has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Palion Medical. Dr. Tepper has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Pulmatrix. Dr. Tepper has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Putnam Associates. Dr. Tepper has received personal compensation in the range of $500-$4,999 for serving as a Consultant for SAI MedPartners. Dr. Tepper has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Satsuma. Dr. Tepper has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Slingshot Insights. Dr. Tepper has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Spherix Global Insights. Dr. Tepper has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Strategy Inc. Dr. Tepper has received personal compensation in the range of $500-$4,999 for serving as a Consultant for System Analytic. Dr. Tepper has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Taylor and Francis. Dr. Tepper has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Teva. Dr. Tepper has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Theranica. Dr. Tepper has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Trinity Partners. Dr. Tepper has received personal compensation in the range of $500-$4,999 for serving as a Consultant for UnityHA. Dr. Tepper has received personal compensation in the range of $500-$4,999 for serving as a Consultant for XOC. Dr. Tepper has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Click Therapeutics. Dr. Tepper has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Miravo. Dr. Tepper has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Neurofront Therapeutics. Dr. Tepper has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Rehaler. Dr. Tepper has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Synapse Medical Communications. Dr. Tepper has received personal compensation in the range of $50,000-$99,999 for serving as a Consultant for Pfizer. Dr. Tepper has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Alphasights. Dr. Tepper has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Perfood. Dr. Tepper has received personal compensation in the range of $500-$4,999 for serving as a Consultant for M3 Global Research. Dr. Tepper has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Scilex. Dr. Tepper has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Synapse Medical Communication. Dr. Tepper has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Tegus. Dr. Tepper has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Catch Therapeutics. Dr. Tepper has received personal compensation in the range of $0-$499 for serving as a Consultant for DocDelta. Dr. Tepper has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Dr Reddy's. Dr. Tepper has received personal compensation in the range of $500-$4,999 for serving as a Consultant for FCB Health. Dr. Tepper has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Gilmartin Capital. Dr. Tepper has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Initiator Pharma. Dr. Tepper has received personal compensation in the range of $500-$4,999 for serving as a Consultant for IQVIA. Dr. Tepper has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Magellan Health. Dr. Tepper has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Nocira. Dr. Tepper has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Slingshot Insights. Dr. Tepper has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Third Bridge. Dr. Tepper has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Tonix. Dr. Tepper has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Vial . Dr. Tepper has received personal compensation in the range of $500-$4,999 for serving as a Consultant for DocDelta. The institution of Dr. Tepper has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Bausch Health. Dr. Tepper has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Dr Reddy's. The institution of Dr. Tepper has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Biohaven. Dr. Tepper has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Aeon. Dr. Tepper has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Abbvie. Dr. Tepper has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for ClickTherapeutics. Dr. Tepper has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for CoolTech. Dr. Tepper has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Lundbeck. Dr. Tepper has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Miravo Healthcare. Dr. Tepper has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Pulmatrix. Dr. Tepper has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Satsuma. Dr. Tepper has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for AbbVie. Dr. Tepper has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Lundbeck. Dr. Tepper has received personal compensation in the range of $50,000-$99,999 for serving on a Speakers Bureau for Pfizer. Dr. Tepper has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Scilex. Dr. Tepper has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Teva. Dr. Tepper has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Tonix. Dr. Tepper has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Dr Reddy's. Dr. Tepper has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Eli Lilly. Dr. Tepper has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Anneal. Dr. Tepper has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Axsome. The institution of Dr. Tepper has received research support from Abbvie. The institution of Dr. Tepper has received research support from Aeon. The institution of Dr. Tepper has received research support from Amgen. The institution of Dr. Tepper has received research support from Annovis. The institution of Dr. Tepper has received research support from Axsome. The institution of Dr. Tepper has received research support from Cassava. The institution of Dr. Tepper has received research support from Cognition. The institution of Dr. Tepper has received research support from Eli Lilly. The institution of Dr. Tepper has received research support from Inibikase. The institution of Dr. Tepper has received research support from Ipsen. The institution of Dr. Tepper has received research support from Lundbeck. The institution of Dr. Tepper has received research support from Merz. The institution of Dr. Tepper has received research support from Pfizer. The institution of Dr. Tepper has received research support from PrecisionMed. The institution of Dr. Tepper has received research support from Revance. The institution of Dr. Tepper has received research support from Suven. The institution of Dr. Tepper has received research support from UCB. The institution of Dr. Tepper has received research support from Biohaven. The institution of Dr. Tepper has received research support from Johnson and Johnson/Intracellular. The institution of Dr. Tepper has received research support from Karuna. The institution of Dr. Tepper has received research support from Neurocrine. Dr. Tepper has received publishing royalties from a publication relating to health care. Dr. Tepper has received personal compensation in the range of $10,000-$49,999 for serving as a CME Speaker with Diamond Headache Clinic. Dr. Tepper has received personal compensation in the range of $500-$4,999 for serving as a CME Speaker with Medical Learning Institute Peerview. Dr. Tepper has received personal compensation in the range of $500-$4,999 for serving as a CME Speaker with Medical Â鶹´«Ã½Ó³»­ Speakers Network. Dr. Tepper has received personal compensation in the range of $5,000-$9,999 for serving as a CME Speaker with Miller Medical Communications. Dr. Tepper has received personal compensation in the range of $500-$4,999 for serving as a CME Speaker with Physicians' Â鶹´«Ã½Ó³»­ Resource. Dr. Tepper has received personal compensation in the range of $10,000-$49,999 for serving as a CME Speaker with WebMD/Medscape. Dr. Tepper has received personal compensation in the range of $500-$4,999 for serving as a CME speaker with American Headache Society. Dr. Tepper has received personal compensation in the range of $500-$4,999 for serving as a CME speaker with Vindico Medical Â鶹´«Ã½Ó³»­. Dr. Tepper has received personal compensation in the range of $500-$4,999 for serving as a CME speaker with HMP Global. Dr. Tepper has received personal compensation in the range of $500-$4,999 for serving as a CMe speaker with Medical Learning Institute Peerview. Dr. Tepper has received personal compensation in the range of $5,000-$9,999 for serving as a Speaker with Consortium for Research Â鶹´«Ã½Ó³»­ Social Awareness and Training In Neurosciences.
Stephen B. Shrewsbury, MD Dr. Shrewsbury has received personal compensation for serving as an employee of Impel NeuroPharma. Dr. Shrewsbury has received stock or an ownership interest from Impel NeuroPharma.
Lahar R. Mehta, MD Dr. Mehta has received personal compensation for serving as an employee of Amylyx Pharmaceuticals.
Juan I. Castiglione, MD Dr. Castiglione has nothing to disclose.
Jennifer R. Cheng, NP The institution of an immediate family member of Ms. Cheng has received research support from NIH.
Sanjay Gandhi, MD Dr. Gandhi has received personal compensation for serving as an employee of Teva Pharmaceuticals.
Robert A. Duarte, MD Dr. Duarte has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for LILLY . Dr. Duarte has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Allergan . Dr. Duarte has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for LILLY . Dr. Duarte has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for LILLY . Dr. Duarte has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Allergan. Dr. Duarte has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Biohaven. Dr. Duarte has received personal compensation in the range of $500-$4,999 for serving as an Expert Witness for HPMB.
Paul Winner, DO, FÂ鶹´«Ã½Ó³»­ Dr. Winner has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Teva. Dr. Winner has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Allergan. Dr. Winner has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Lundbeck . Dr. Winner has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Amgen. Dr. Winner has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Allergan. Dr. Winner has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Lundbeck. Dr. Winner has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Teva. Dr. Winner has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for lilly. The institution of Dr. Winner has received research support from Amgen. The institution of Dr. Winner has received research support from Allergan. The institution of Dr. Winner has received research support from Lundbeck . The institution of Dr. Winner has received research support from Novartis. The institution of Dr. Winner has received research support from Lilly. The institution of Dr. Winner has received research support from Teva. The institution of Dr. Winner has received research support from Supernus. The institution of Dr. Winner has received research support from Biogen. The institution of Dr. Winner has received research support from Avinar. The institution of Dr. Winner has received research support from SAMUS.
Raed Alroughani, MD, FÂ鶹´«Ã½Ó³»­ Dr. Alroughani has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen, AstraZeneca, Novartis, Merck, Roche, Sanofi. Dr. Alroughani has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for AstraZeneca, Biogen, Novartis, Merck, Roche, Sanofi.
Sara Habib, MD Dr. Habib has nothing to disclose.
Karissa Johnston Karissa Johnston has nothing to disclose.
Ahmad Al-Awwad, MD Dr. Al-Awwad has nothing to disclose.
Susan Hutchinson Susan Hutchinson has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Alder Pharmaceutical. Susan Hutchinson has received personal compensation in the range of $50,000-$99,999 for serving as a Consultant for Allergan Pharmaceutical . Susan Hutchinson has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Amgen Pharmaceutical. Susan Hutchinson has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Biohaven . Susan Hutchinson has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Currax Pharmaceutical . Susan Hutchinson has received personal compensation in the range of $500-$4,999 for serving as a Consultant for electroCore. Susan Hutchinson has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Lilly Pharmaceutical . Susan Hutchinson has received personal compensation in the range of $0-$499 for serving as a Consultant for Lundbeck Pharmaceutical. Susan Hutchinson has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novartis. Susan Hutchinson has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Teva. Susan Hutchinson has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Theranica. Susan Hutchinson has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Upsher Smith. Susan Hutchinson has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Impel Pharmaceutical . Susan Hutchinson has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Allergan . Susan Hutchinson has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Lilly Pharmaceutical . Susan Hutchinson has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Allergan/AbbVie. Susan Hutchinson has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Amgen. Susan Hutchinson has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Biohaven . Susan Hutchinson has received personal compensation in the range of $100,000-$499,999 for serving on a Speakers Bureau for Lilly Pharmaceutical . Susan Hutchinson has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Lundbeck . Susan Hutchinson has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Teva . Susan Hutchinson has received personal compensation in the range of $10,000-$49,999 for serving as an officer or member of the Board of Directors for Headache Cooperative of the Pacific . Susan Hutchinson has received publishing royalties from a publication relating to health care.
Gilbert J. L'Italien Gilbert J. L'Italien has received personal compensation for serving as an employee of Biohaven Pharmaceuticals. Gilbert J. L'Italien has stock in biohaven pharmaceuticals.
Russell Nichols Russell Nichols has received personal compensation for serving as an employee of Eli Lilly and Company. Russell Nichols has received stock or an ownership interest from Eli Lilly and Company.
Monique M. Montenegro, MD Dr. Montenegro has nothing to disclose.
Larisa Yedigarova Larisa Yedigarova has received personal compensation for serving as an employee of AbbVie. Larisa Yedigarova has received stock or an ownership interest from AbbVie.
Merrill M. Brady Moe, MD Dr. Brady Moe has nothing to disclose.
Linda Wietecha, RN, MS Ms. Wietecha has received personal compensation for serving as an employee of Eli Lilly and Company. Ms. Wietecha has received stock or an ownership interest from Eli Lilly and Company.
Leonard Shou, DO Dr. Shou has nothing to disclose.
Egilius L. Spierings, MD, PhD Dr. Spierings has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Manistee. Dr. Spierings has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Lundbeck. Dr. Spierings has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Lilly. Dr. Spierings has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Abbvie.
Monika Maier Peuschel Monika Maier Peuschel has received personal compensation for serving as an employee of Novartis Pharma . Monika Maier Peuschel has received stock or an ownership interest from Novartis Pharma AG.
Richard Kovacs Richard Kovacs has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Eli Lilly. Richard Kovacs has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Cook Research Inc. Richard Kovacs has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Prilenia. Richard Kovacs has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for University Southern California. Richard Kovacs has received personal compensation in the range of $100,000-$499,999 for serving as an officer or member of the Board of Directors for American College of Cardiology. The institution of Richard Kovacs has received research support from NHLBI.
Erafat Rehim, MD Dr. Rehim has nothing to disclose.
Dulanji Kuruppu, MD Dr. Kuruppu has received personal compensation for serving as an employee of Eli Lilly and Company. Dr. Kuruppu has received stock or an ownership interest from Eli Lilly and Company.
Bruno Colombo Bruno Colombo has nothing to disclose.
Gabriella O'Fallon Ms. O'Fallon has nothing to disclose.
Scott Powers, PhD Scott Powers, PhD has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Theranica. The institution of Scott Powers, PhD has received research support from NIH. The institution of Scott Powers, PhD has received research support from PCORI. The institution of Scott Powers, PhD has received research support from Cystic Fibrosis Foundation. Scott Powers, PhD has a non-compensated relationship as a Associate Editor with The Journal HEADACHE that is relevant to Â鶹´«Ã½Ó³»­ interests or activities. Scott Powers, PhD has a non-compensated relationship as a Member Board of Directors with American Headache Society that is relevant to Â鶹´«Ã½Ó³»­ interests or activities.
Andrew Buchanan No disclosure on file
Roberta Messina, MD, PhD Dr. Messina has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Pfizer. Dr. Messina has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Pfizer. Dr. Messina has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Lundbeck. Dr. Messina has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Teva. Dr. Messina has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Organon. Dr. Messina has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Abbvie. Dr. Messina has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Eli Lilly.
Visar Berisha Visar Berisha has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Cytokinetics. Visar Berisha has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Boehringer Ingelheim. Visar Berisha has received personal compensation in the range of $10,000-$49,999 for serving as an officer or member of the Board of Directors for Aural Analytics. Visar Berisha has received stock or an ownership interest from Aural Analytics. The institution of Visar Berisha has received research support from Boheringer Ingelheim. Visar Berisha has received intellectual property interests from a discovery or technology relating to health care.
Michael J. Marmura, MD, FÂ鶹´«Ã½Ó³»­ Dr. Marmura has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Lundbeck. Dr. Marmura has received personal compensation in the range of $500-$4,999 for serving as a Consultant for AbbVie. The institution of Dr. Marmura has received research support from Teva. The institution of Dr. Marmura has received research support from AbbVie. The institution of Dr. Marmura has received research support from Axsome. The institution of Dr. Marmura has received research support from Pfizer. Dr. Marmura has received publishing royalties from a publication relating to health care. Dr. Marmura has received publishing royalties from a publication relating to health care. Dr. Marmura has received publishing royalties from a publication relating to health care.
Thomas Finnegan, Jr., PhD Dr. Finnegan has nothing to disclose.
Donald Kellerman No disclosure on file
Nada A. Hindiyeh, MD Dr. Hindiyeh has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Eli Lilly. Dr. Hindiyeh has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Eli Lilly. Dr. Hindiyeh has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alder/Lundbeck. Dr. Hindiyeh has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Amgen. Dr. Hindiyeh has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Impel. Dr. Hindiyeh has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Lundbeck .
Robert Fishman, MD Dr. Fishman has nothing to disclose.
Mary Haywood Mary Haywood has nothing to disclose.
Maria Jeleva Maria Jeleva has received personal compensation for serving as an employee of Impel NeuroPharma.
Mirela Cerghet, MD, PhD, FÂ鶹´«Ã½Ó³»­ Dr. Cerghet has nothing to disclose.
Abraham J. Nagy, MD No disclosure on file